

3631-0104P

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

09/774,012

PRIORITY DATE CLAIMED

July 20, 1998

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

INTERNATIONAL APPLICATION NO.

PCT/DK99/00408

INTERNATIONAL FILING DATE

July 16, 1999

TITLE OF INVENTION

NOVEL METHODS FOR THE IDENTIFICATION OF LIGAND AND TARGET BIOMOLECULES

APPLICANT(S) FOR DO/EO/US

HALKIER, Torben; JESPERSEN, Lene and JENSEN, Allan

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39 (1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☒ is transmitted herewith (required only if not transmitted by the International Bureau). WO 00/05406
 - b. ☒ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(3)).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(2)).
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern document(s) or information included:

11. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98./International Search Report
12. ☒ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A **FIRST** preliminary amendment.
☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items or information:
 - 1.) International Preliminary Examination Report (PCT/IPEA/409) w/Annexes
 - 2.) PCT Request Form (PCT/RO/101)
 - 3.) Seven (7) sheets of Formal Drawings
 - 4.) Letter
 - 5.) Sequence Listing (15 pages)



U.S. APPLICATION NO. (if known, see 37 CFR 1.5) 097744012		INTERNATIONAL APPLICATION NO. PCT/DK99/00408		ATTORNEY'S DOCKET NUMBER 3631-0104P	
---	--	---	--	--	--

<p>17. <input checked="" type="checkbox"/> The following fees are submitted.</p> <p>BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO. \$1,000.00</p> <p>International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$860.00</p> <p>International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO. \$710.00</p> <p>International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$690.00</p> <p>International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4). \$100.00</p> <p>ENTER APPROPRIATE BASIC FEE AMOUNT =</p> <p>Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).</p> <table border="1" style="width:100%; border-collapse: collapse;"> <tr> <th style="width:20%;">CLAIMS</th> <th style="width:20%;">NUMBER FILED</th> <th style="width:20%;">NUMBER EXTRA</th> <th style="width:20%;">RATE</th> <th style="width:20%;"></th> </tr> <tr> <td>Total Claims</td> <td>76 - 20 =</td> <td>56</td> <td>X \$18.00</td> <td>\$ 1,008.00</td> </tr> <tr> <td>Independent Claims</td> <td>1 - 3 =</td> <td>0</td> <td>X \$80.00</td> <td>\$</td> </tr> <tr> <td colspan="4">MULTIPLE DEPENDENT CLAIM(S) (if applicable) Yes</td> <td>+ \$270.00 \$ 270.00</td> </tr> <tr> <td colspan="4" style="text-align: right;">TOTAL OF ABOVE CALCULATIONS =</td> <td>\$ 2,138.00</td> </tr> <tr> <td colspan="4">Reduction of 1/2 for filing by small entity, if applicable. Applicant claims Small Entity Status in accordance with 37 CFR 1.27.</td> <td>\$</td> </tr> <tr> <td colspan="4" style="text-align: right;">SUBTOTAL =</td> <td>\$ 2,138.00</td> </tr> <tr> <td colspan="4">Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).</td> <td>\$</td> </tr> <tr> <td colspan="4" style="text-align: right;">TOTAL NATIONAL FEE =</td> <td>\$ 2,138.00</td> </tr> <tr> <td colspan="4">Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +</td> <td>\$ 40.00</td> </tr> <tr> <td colspan="4" style="text-align: right;">TOTAL FEES ENCLOSED =</td> <td>\$ 2,178.00</td> </tr> <tr> <td colspan="4"></td> <td>Amount to be: \$</td> </tr> <tr> <td colspan="4"></td> <td>refunded \$</td> </tr> <tr> <td colspan="4"></td> <td>charged \$</td> </tr> </table>	CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		Total Claims	76 - 20 =	56	X \$18.00	\$ 1,008.00	Independent Claims	1 - 3 =	0	X \$80.00	\$	MULTIPLE DEPENDENT CLAIM(S) (if applicable) Yes				+ \$270.00 \$ 270.00	TOTAL OF ABOVE CALCULATIONS =				\$ 2,138.00	Reduction of 1/2 for filing by small entity, if applicable. Applicant claims Small Entity Status in accordance with 37 CFR 1.27.				\$	SUBTOTAL =				\$ 2,138.00	Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	TOTAL NATIONAL FEE =				\$ 2,138.00	Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				\$ 40.00	TOTAL FEES ENCLOSED =				\$ 2,178.00					Amount to be: \$					refunded \$					charged \$	<p>CALCULATIONS PTO USE ONLY</p>
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE																																																																				
Total Claims	76 - 20 =	56	X \$18.00	\$ 1,008.00																																																																			
Independent Claims	1 - 3 =	0	X \$80.00	\$																																																																			
MULTIPLE DEPENDENT CLAIM(S) (if applicable) Yes				+ \$270.00 \$ 270.00																																																																			
TOTAL OF ABOVE CALCULATIONS =				\$ 2,138.00																																																																			
Reduction of 1/2 for filing by small entity, if applicable. Applicant claims Small Entity Status in accordance with 37 CFR 1.27.				\$																																																																			
SUBTOTAL =				\$ 2,138.00																																																																			
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$																																																																			
TOTAL NATIONAL FEE =				\$ 2,138.00																																																																			
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				\$ 40.00																																																																			
TOTAL FEES ENCLOSED =				\$ 2,178.00																																																																			
				Amount to be: \$																																																																			
				refunded \$																																																																			
				charged \$																																																																			


a. ☒ A check in the amount of \$ **2,178.00** to cover the above fees is enclosed.

b. ☐ Please charge my Deposit Account. No. _____ in the amount of \$ _____ to cover the above fees.
 A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any
 overpayment to Deposit Account No. 02-2448.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

Send all correspondence to:
Birch, Stewart, Kolasch & Birch, LLP or Customer No. 2292
P.O. Box 747
Falls Church, VA 22040-0747
(703)205-8000


 SIGNATURE
 for SVENSSON, LEONARD R.
 NAME
 #30,330 (LRS)
 REGISTRATION NO.

09/744012

09/744012

JC07 Rec'd PCT/PTO 19 JAN 2001

PATENT
3631-0104P

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: HALKIER, Torben et al
Int'l. Appl. No.: PCT/DK99/00408
Appl. No.: NEW Group:
Filed: January 19, 2001 Examiner:
For: NOVEL METHODS FOR THE
IDENTIFICATION OF LIGAND AND TARGET
BIOMOLECULES

PRELIMINARY AMENDMENT

BOX PATENT APPLICATION

Assistant Commissioner for Patents
Washington, DC 20231

January 19, 2001

Sir:

The following Preliminary Amendments and Remarks are respectfully submitted in connection with the above-identified application.

AMENDMENTS

IN THE SPECIFICATION:

Please amend the specification as follows:

Before line 1, insert --This application is the national phase under 35 U.S.C. § 371 of PCT International Application No. PCT/DK99/00408 which has an International filing date of July 16, 1999, which designated the United States of America.--

IN THE CLAIMS:

Please amend the following claims.

Claim 8

Line 1, change "any one of the preceding claims" to
--claim 1--.

Claim 9

Line 1, change "any one of the preceding claims" to
--claim 1--.

Claim 10

Line 1, change "any of the preceding claims" to
--claim 1--.

Claim 11

Line 1, change "any one of claims 1-9" to --claim 1--.

Claim 12

Line 1, change "any one of the proceeding claims" to
--claim 1--.

Claim 14

Line 1, change "any one of the preceding claims" to
--claim 1--.

Claim 15

Line 1, change "any one of the preceding claims" to
--claim 1--.

Claim 19

Line 1, change "any one of the preceding claims" to
--claim 1--.

Claim 20

Line 1, change "any one of the preceding claims" to
--claim 1--.

Claim 24

Line 1, change "any of the preceding claims" to
--claim 1--.

Claim 29

Line 1, change "any one of claims 25-28" to
--claim 25--.

Claim 30

Line 1, change "any one of claims 25-29" to
--claim 25--.

Claim 32

Line 1, change "any one of claims 25-31" to
--claim 25--.

Claim 34

Line 1, change "any of the preceding claims" to
--claim 1--.

Claim 39

Line 1, delete "or 38".

Claim 40

Line 1, change "any one of the preceding claims" to
--claim 1--.

Claim 41

Lines 3 and 4, change "any one of the preceding claims" to -claim 1--.

Docket No. 3631-0104P

Claim 42

Line 3, change "any one of claims 1-40" to -claim 1--.

Claim 43

Lines 1 and 2, change "any one of claims 1-40" to
--claim 1--;

Lines 9 and 10, change "any one of claims 1-40" to.
--claim 1--.

Claim 49

Line 1, change "any of claims 44-48" to --claim 44--.

Claim 50

Line 6, change "any one of claims 44-49" to --claim
44--.

Claim 53

Line 3, change "any one of claims 1-40" to --claim
1--;

Line 5, change "any one of claims 44-49" to --claim
44--.

REMARKS

The specification has been amended to provide a cross-reference to the previously filed International Application. The claims have been amended to delete improper multiple dependencies.


Entry of the present amendment and favorable action on the merits are respectfully requested.

Docket No. 3631-0104P

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By  #32868
for Leonard R. Svensson, #30,330

LRS/slk
3631-0104P

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

(Rev. 04/19/2000)

NOVEL METHODS FOR THE IDENTIFICATION OF LIGAND AND TARGET BIOMOLECULES

FIELD OF THE INVENTION

The present invention pertains to a novel method for the identification/preparation of peptides or ribonucleic acids capable of modulating the activity *in vivo* of target enzymes in eukaryotic cells. More specifically, the invention provides a method for identification/preparation of hitherto unknown enhancers as well as inhibitors of *in vivo* enzyme activity in eukaryotic cells. Furthermore, the invention relates to methods for identification of unknown interactions (*i.e.* identification of a target and/or a ligand but also of hitherto unknown interactions between known ligands and known targets). These novel methods employ enzyme inhibitor structures as scaffolds in order to intracellularly display potentially biologically active peptides or ribonucleic acids in a stable form. Also disclosed herein are methods for the preparation of the hitherto unknown ligands or targets as well as methods for the preparation of vectors and transformed cells carrying the genetic information encoding these ligands and targets. Finally, the invention relates to a method for the preparation of a medicinal product which is based on initial identification of targets or ligands according to the present invention.

BACKGROUND OF THE INVENTION

The CellScreen™ technique is a method which allows for the identification of peptide sequences having biological activity *in vivo* and which is disclosed in WO 96/38553. In short, libraries of random peptides are expressed intracellularly in eukaryotic (eg. mammalian) cells, such that one cell expresses one single or a few heterologous short peptides. Cells that change a preselected phenotype under certain conditions can be

isolated and the peptide that they express can hence be identified. The intracellular component with which the peptide interacts (the target molecule) may subsequently be obtained using e.g. affinity columns carrying the immobilized synthetic
5 peptide.

Although the CellScreen™ technology has shown great promise for identifying new drug targets, it is an inherent problem that the intracellular environment is relatively hostile to many heterologous expression products. In other words, inter-
10 esting peptide or nucleic acid sequences which potentially are capable of interacting with an important target molecule may be degraded or inactivated inside the cell before any effect on phenotype can be detected.

OBJECT OF THE INVENTION

15 It is an object of the invention to provide improvements in the CellScreen™ technology by overcoming the above-mentioned problems of potential instability of expressed sequences. Furthermore, it is an object of the invention to expand the utility of the CellScreen™ technology to also encompass
20 screening in prokaryotic cells.

SUMMARY OF THE INVENTION

A significant number of enzyme activity modulators of plant, microbial and eukaryotic cell origin have been described, cf. below.

25 Since many of the naturally occurring processes inside cells are regulated by enzymes, the inventors disclose herein a method for expression of large intracellular libraries of such

enzyme activity modulators in which the active site of said enzyme activity modulators have been altered by introduction of stretches of randomized amino acid sequences or by introduction of random nucleotides at specific sites in the active site. This creates libraries of putative modulators capable of modulating the activity of an array of different enzymes inside cells. By expressing these modulators in cell lines according to a novel variation of the CellScreen™ technology the enzymatic regulatory mechanisms inside the individual cell in said cell line will be affected differently leading to different phenotypic properties such as e.g. resistance towards hypoglycemia, cytokine killing, toxic compounds, virus infection etc.

The main advantage of using known enzyme activity modulators such as enzyme *inhibitors* as scaffolds is that many of these in their native form are stable in the intracellular environment. The problem of using e.g. antibody fragments as scaffolds for intracellular presentation of random peptides is that many such antibody fragments are susceptible to the proteolytic and reducing intracellular environment and therefore are unsuitable as intracellular scaffolds. On the other hand, enzyme activity modulators can, if carefully tailored, maintain their intracellular stability and at the same time incorporate random sequences which are screened for biological activity. Furthermore, the effectivity of such a screen for biologically active substances will be higher than if using an unstable scaffold (such as a e.g. a coiled coil structure) or no scaffold at all, since none or only a very limited number of the randomized sequences will be degraded before they can exert their effects in the cells. Finally, a majority of such enzyme activity modulators have an active site which is the perfect position in the molecule to modify, since the active site is normally presented in a stable configuration to the environment.

Hence, one aspect of the invention pertains to a method for identifying an *in vivo* active modulator of activity of a target enzyme, the method comprising the steps of (a) preparing a pool of expression vectors, each vector of said pool
 5 containing at least one member from a library of randomly modified nucleotide sequences derived from a parent nucleotide sequence encoding a parent peptide or parent ribonucleic acid which modulates the target enzyme activity, (b) transforming a population of substantially identical cells with said vectors
 10 of said pool so as to obtain transformed cells, said substantially identical cells being ones which harbour the target enzyme, (c) culturing said transformed cells under conditions facilitating expression of said randomly modified nucleotide sequences, (d) examining said transformed cells and isolating
 15 transformed cell(s) wherein the activity of the target enzyme is modulated, and (e) identifying the modulator by determining said randomly modified nucleotide sequence of said vector present in cell(s) isolated in step (d) and/or determining the amino acid sequence or the ribonucleic acid sequence of the
 20 expression product encoded by said randomly modified nucleotide sequence.

In this aspect of the invention it is normally preferred that the randomly modified nucleotide sequences consist of 1) an invariable part of the parent nucleotide sequence, and 2)
 25 random nucleotides. In line with the above, the invariable part of the parent nucleotide sequence preferably encodes a scaffold portion of the parent peptide or of the parent ribonucleic acid which serves to stabilize said polypeptide fragment or ribonucleic acid fragment.

30 As mentioned above, the use of enzyme modulator scaffolds also provides for expression of *stable*, biologically active modulators which interact with other biomolecules than enzymes. In other words, in cases where random nucleotides are inserted in

a scaffold structure, the outcome will be a stable expression product, the activity of which does not necessarily have anything to do with enzyme activity modulation.

Hence, another part of the invention is a method for identifying a modulator in the form of a biologically active polypeptide fragment or ribonucleic acid fragment which is capable of detectably modulating, *in vivo*, a phenotypic trait in a cell, the method comprising the steps of

(a) preparing a pool of expression vectors, each vector of said pool containing at least one member from a library of randomly modified nucleotide sequences derived from a parent nucleotide sequence encoding a parent peptide or parent ribonucleic acid which *in vivo* modulates activity of a known enzyme, wherein the randomly modified nucleotide sequences comprise

- an invariable part encoding a scaffold portion of the parent peptide or of the parent ribonucleic acid, said scaffold portion serving to stabilize said polypeptide fragment or ribonucleic acid fragment, and

- random nucleotides,

(b) transforming a population of substantially identical cells with said vectors of said pool so as to obtain transformed cells, (c) culturing said transformed cells under conditions facilitating expression of said randomly modified nucleotide sequences, (d) examining said transformed cells and isolating transformed cell(s) wherein the preselected phenotypic trait is modulated by the presence of the expressed randomly modified nucleotide sequence, and (e) identifying the modulator by determining said randomly modified nucleotide sequence of said

vector present in cell(s) isolated in step (d) and/or determining the amino acid sequence or the ribonucleic acid sequence of the expression product encoded by said randomly modified nucleotide sequence.

Finally, the invention also pertains to the general use of intracellularly stable scaffold proteins, ribonucleotides, or fragments thereof for the presentation of random sequences in the CellScreen™ technology. As mentioned above, although the concept of using scaffold molecules has been discussed in the prior art, the issue of the *stability* of the scaffold system has not been detailed.

The stability and usefulness of a putative intracellular scaffold is dependent on a number of factors. First of all, it is essential that the relevant cell wherein the scaffold is to be expressed is capable of expressing the scaffold molecule in a functional form; that is, in prokaryotic systems some eukaryotic proteins will not fold correctly, hence rendering the use of such a protein unsuitable as a scaffold in that type of cell. Second, the scaffold should be relatively resistant to the reducing and catalytic environment inside intact cells. However, even when a scaffold molecule is relatively susceptible to the inactivating nature of the intracellular environment, this can be remedied if the production rate of the scaffold molecule is sufficiently high.

In steady state, the intracellular concentration of a scaffold molecule will be a function of the following formula:

$$C_{scaffold} = \frac{R_p}{R_d}$$

-where R_p is the rate of production of the scaffold molecule (moles · s⁻¹) and R_d is the inactivation constant for the scaffold molecule (l · s⁻¹), i.e. the rate of inactivation of the scaffold molecule is determined by $\frac{\delta M}{\delta t} = R_d C_{scaffold}$ (which, in steady state, of course equals R_p . In other words, when assessing the suitability of a potential scaffold molecule, it should according to the present invention be tested whether the molecule can be kept at a sufficiently high concentration

tially identical cells, is present in an effective concentration and in a functional state.

In other words, it is essential that the suitability of the scaffold molecule is evaluated prior to performing the steps
5 of the CellScreen™ technology in order to confirm that the scaffold molecule in unmodified form can be expressed and maintained at a sufficiently high concentration/activity in the cellular system where the method of the invention is to be exercised.

10 According to WO 96/38553, the isolation of a drug target molecule can be made more efficient if the random peptide sequences are inserted into larger polypeptides functioning as scaffolds for display of the random amino acid sequences. Such scaffolds would probably also lead to higher affinity interaction with the target molecule.
15

Nothing is, however, mentioned about the use of scaffolds derived from naturally occurring protein inhibitors of enzymes. Inhibition of enzymatic activity by such inhibitors - as opposed to the simple binding of a target protein inside a
20 cell as was suggested in the CellScreen™ technology - is a much more efficient way to affect intracellular biochemical events.

DETAILED DISCLOSURE OF THE INVENTION

Definitions

25 In the following, a number of terms will be defined for the purposes of the present disclosure:

A "modulator" is in the present context a biomolecule which, when expressed *in vivo*, effects the activity of another biomolecule in the cell. Thus, the modulator in essence can inhibit or enhance the activity of the biomolecule. Furthermore, the modulator can interact directly with the biomolecule, but the effect might as well be indirect, i.e. the activity change of the biomolecule is brought about by changes in the cell's biochemical machinery, changes which are ultimately the result of the presence of the expression product of the randomized nucleic acid sequence.

A "randomly modified nucleotide sequence" is a nucleotide sequence which in a number of positions has been subjected to insertion or substitution by nucleotides, the nature of which cannot be predicted. In many cases the random nucleotides or nucleotide sequences inserted will be "completely random" (e.g. as a consequence of randomized synthesis or PCR-mediated mutagenesis). However, as will appear from the disclosure below, the random sequences can also include sequences which have a common functional feature (e.g. reactivity with a ligand of the expression product) or the random sequences can be random in the sense that the ultimate expression product is of completely random sequence with e.g. an even distribution of the different amino acids.

"Substantially identical cells" is a term herein intended to designate cells which all exhibit a specific phenotypic trait in such a manner that a change in the expression of said trait in one cell due to an interaction effected by the introduction of random nucleotides according to the inventive methods would also occur in one of the other substantially identical cells had these been transformed with the same vector. In other words, the important parameter to assess when choosing substantially identical cells in the inventive methods is whether an observed change in one cell's exhibition of the phenotypic

trait can be taken as an indication that any other cell in the population would have behaved the same way as a consequence of the same change. Hence, substantially identical cells can for instance be clonal cells or cells of a cell line or they can
5 be cells of a cell culture or a tissue culture.

A "phenotypic trait" is the observable result of a certain gene composition in a cell (genotype), *i.e.* a property of a cell (detected by chemical, physical, immunological or any other suitable means) which depends on the presence of one or
10 several genes and the expression rate thereof. Thus, the phenotypic trait can be any of a number of different properties: activity of an enzyme, effects of interaction between receptors and ligands, cell survival rate, presence or absence of an antigen, expression rate, etc.

15 "Peptide" is in the present context intended to mean both short peptides of from 2 to 10 amino acid residues, oligopeptides of from 11 to 100 amino acid residues, and polypeptides of more than 100 amino acid residues. Furthermore, the term is also intended to include proteins, *i.e.* functional biomole-
20 cules comprising at least one polypeptide; when comprising at least two polypeptides, these may form complexes, be covalently linked, or may be non-covalently linked. The polypeptide(s) in a protein can be glycosylated and/or lipidated and/or comprise prosthetic groups.

25 When using the term "biologically active" to designate a molecule is herein meant that the molecule in question exhibits a detectable effect on *living* cells, *i.e.* that the molecule interacts with the biology of the living cell so as to produce an effect which can be recognized as a change in the
30 cell's phenotype.

"In vivo" is herein mean to designate the environmental conditions inside living cells (*i.e.* cells which are metabolically active and can maintain their vital functions); the living cells may be kept in culture or may be present in a natural habitat (e.g. functioning as part of a larger, multicellular organism). Thus, the term "in vivo" also refers to *in vitro* culturing of cells as long as the effect being observed is taking place in the living cell.

"Transformation": A process by which the genetic material carried by an individual cell is altered by incorporation of exogenous DNA into its genome.

"Transfection": The uptake, incorporation, and expression of recombinant DNA by cells.

"Transduction": The transfer of genetic information from one cell to another by way of a viral vector.

The term "effective part" when used in the context of a protein, peptide, or ribonucleic acid is in the present context intended to mean a part (e.g. a subsequence or, in the case of an n-meric protein, a less-than-n-meric molecule) which has retained the desired functionality of the native molecule from which the protein or peptide is derived. For instance, in the case of CI-2A only the truncated form of the molecule seems to be necessary to ensure expression of the active inhibitor intracellularly, and hence the truncated form of that molecule constitutes an effective part of CI-2A; cf. also the Examples herein.

Unless otherwise indicated, nucleotide sequences are presented herein in the 5'-3' direction and amino acid sequences are presented so as to set out with the N-terminus at the left.

General properties of the inventive method

In general, the disclosures in WO 96/38553 and WO 97/27212 relating

5 to preparation of randomized sequences, to the choice of fusion partners (except for the choice of scaffolds) for the random sequences, to the choice and composition of targeting sequences, to the choice of nucleic acids to be randomly modified, to the choice of randomization method, to the methods of introducing the nucleic acids into the
10 relevant cell type, to the choice of (retroviral) vectors (where applicable), to the method of producing the vectors, the choice of promoters, to the choice of packaging cells (where applicable), to the methods of concentrating infectious virions from the packaging cells (where applicable), to the choice of substantially identical cells to
15 use in the method, to the type of phenotypic changes detected, to the manner in which the change is detected, to methods of isolating the phenotypically changed cells, to the isolation and sequence determination of the randomly modified sequences, to the isolation and character-
20 ization of the target for the randomized product, to screening methods, and to the choice of applications of the methods

also are relevant for the purposes of the present invention.

25 Therefore, the disclosures of these two patent applications are hereby incorporated by reference herein. However, since both of these references are focussed on the use of the general principle in higher eukaryotic cells, the present disclosure will also detail on embodiments pertaining to the use in
30 prokaryotic systems, cf. below. However, the more general part of the two above-referenced disclosures which without any difficulty for the skilled person could be applied in the

context of a prokaryotic system are also regarded as relevant and important embodiments of the present invention insofar as it relates to the use of the methods in prokaryotic systems.

It is normally preferred that the transformed cells which are
 5 being examined in step (d) predominantly carries (and expresses) one single copy of the vector. By ensuring this, the interpretation of a change in phenotype of the cells becomes a much easier task, whereas the interpretation of a phenotype change in cells expressing more than one single randomized
 10 sequence renders unclear which of the transforming vectors is responsible for the change.

To ensure that predominantly one vector has transformed each of the cells examined it is e.g. feasible that the transformation step (b) is performed under such conditions that the
 15 cells transformed are predominantly or at most transformed with one single vector from said pool (this can e.g. be achieved by adjusting the concentration of infectious virions in embodiments of the invention where the transformation is obtained by means of transduction), or wherein, prior to
 20 carrying out step (d), cells being transformed with more than one vector from said pool are substantially excluded from the further steps. This latter option requires that it is possible to quantify the number of transforming vectors and this can be achieved by including a detectable marker in the expression
 25 product, e.g. a fluorescent probe. Another option is to re-screen cells which exhibit changes in phenotype, thereby ascertaining whether more than one vector has transformed the cell.

It will be understood that the molecule chosen for the purpose
 30 of being a scaffold, and wherein the random sequences are ultimately introduced, can be either a peptide sequence or a nucleic acid sequence, such as an RNA fragment interfering (in

an antisense-manner) with mRNA, tRNA or with a ribozyme. Alternatively, such an RNA fragment could exhibit ribozyme activity itself, thereby having an indirect influence on the expression rate of other enzymes. At any rate, the resulting
5 product, i.e. the randomized expression product, can be a peptide or a ribonucleic acid such as a ribozyme.

One important feature of the scaffold is, as mentioned above, that it is stable towards proteolytic attack and/or is insensitive to a reducing environment, such as the one which
10 is found intracellularly.

In preferred embodiments of the invention the random nucleotides are introduced in part(s) of the parent nucleotide sequence which encode(s) the active site(s) of the parent peptide or parent ribonucleic acid, or the part(s) which
15 encode(s) structure(s) interfering with the active site(s). As discussed above, the active site (as well as other exposed structures of the scaffold) need to be stably presented to the environment in order to be able to interact with other biomolecules. Hence, preferably the *invariable* part of the
20 nucleotide sequence encodes truncated parts of the parent peptide or parent ribonucleic acid sufficient to maintain stability of the randomized product.

In some embodiments it is preferred that the invariable part of the parent nucleotide sequence encodes a peptide which is
25 free from disulfide bridges. This is due to the fact that disulfide bridges are not formed in the nucleus or in the cytosol. Hence, in cases where the scaffold must be in a functional state when present in the nucleus or the cytosol, it would normally be preferable to use a scaffold which does not
30 contain disulfide bridges or which do not rely on these in order to maintain stability and functionality. On the other hand, in embodiments where it is desired that the randomized

expression product is confined to the ER, or to another compartment allowing for the presence of stable disulfide bridges, before the randomized sequence is presented to the environment in a satisfactory manner, it is of course desirable that the invariable part of the parent nucleotide sequence encodes a peptide having disulfide bridges, because the chances of having a correctly folded and functional scaffold outside such compartments is relatively small.

It will be understood that the random nucleotides are preferably introduced in the form of an insertion or a substitution into the parent nucleotide sequence, optionally in combination with deletion(s) in the parent nucleotide sequence. Deleted sequences in the parent polypeptide could e.g. be parts of an active site, the presence of which in unaltered form is toxic or otherwise deleterious to the transformed cells.

The number of random nucleotides introduced can vary to a great degree but normally the number is between 3 and about 100. In this range it is preferred that at least 5, such as at least 7, and better, at least 9-12 random nucleotides are introduced. On the other hand, it is preferred that at most 90, such as at most 70 or 80 random nucleotides are introduced. The most preferred number of introduced randomized nucleotides varies between 15-60, preferably 20-55 or 25-50 nucleotides. Especially preferred numbers of random nucleotides are 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, and 60 nucleotides.

The random nucleotides are introduced in the scaffold in the form of nucleotide sequences and/or in the form of single random nucleotides introduced at specific sites in the parent nucleotide sequence. A variation is to substitute a part of

the scaffold sequence with a sequence which retains parts of the scaffold sequence (e.g. those which are essential for stability/functionality) but where other parts are randomized.

The random nucleotides are preferably selected from the group
5 consisting of

- synthetic, completely random deoxyribonucleotides;
- synthetic random DNA sequences, wherein limitation on randomization of some nucleotides is introduced so as to limit the number of available sequences and/or to avoid
10 undesired stop codons and/or to facilitate introduction of post-translational modifications of expressed peptide(s);
- synthetic random DNA sequences as in (1) or (2) coupled to a sequence encoding a purification tag; and
- 15 - CDR encoding nucleotide sequences isolated from a library of immune-competent cells raised against an antigen (in this embodiment it is preferred that CDR encoding nucleotide sequences encode CDR-3 peptide sequences).

The latter type of "randomization" actually introduces a restriction on randomness which ensures that the sequences
20 introduced encodes an antigen recognizing region. It is, however, well known that a polyclonal immune response against an antigen consist of a large number of immune competent cells which all react with the same antigen (or perhaps even with
25 the same epitope) but the correlation between amino acid sequences of the CDRs and recognition of the epitope(s) is virtually impossible to deduce.

An alternative way to introduce limitations on the randomness of the nucleic acid sequences which are ultimately tested in
30 the substantially identical cells is the following: Upon preparation of the vectors, they are used in a 1st round of phage display, where the phages transformed with the vectors

are panned against a library containing a ligand of choice. As for the technique of employing CDR encoding sequences, the result is that the sequences which are ultimately tested in the substantially identical cells are "unpredictable" (and
5 thereby random) but nevertheless selected on the basis of a functional feature. Again, the lack of known correlation between nucleic acid sequences and the interaction in three-dimensional space between the expression product and a ligand of choice has the consequence that the tested subgroup of
10 sequences still is randomized.

In a special embodiment of the above-technique where the method of the invention is combined with phage display, both test systems are repeated in an alternating manner, that is a shuffling between intracellular expression in the substantial
15 identical cells and panning of a phage library.

In order to obtain an controlled distribution of amino acids in the randomized peptides, when the modulator is a peptide, it is practical that the random nucleotides are prepared by random codon synthesis where defined DNA codons are synthe-
20 sized in a random order; a thorough description of this principle is given in WO 96/38553, cf. Example 1 therein. The preferred embodiment in this context is one wherein the relative amount of synthesized codons ensure that all encoded amino acids will be present with substantially the same fre-
25 quency in the total of encoded polypeptide fragments, i.e. that the chance of encountering one specific amino acid in a library peptide is substantially the same as for any other encoded amino acid.

In order to introduce the randomized fragments properly into
30 the vectors, it is according to the invention preferred that the random nucleotides are introduced into the expression vector by the principle of site directed PCR-mediated mutagen-

Apart from having the randomized fragment of the expression

sent invention, it is often necessary to couple the random

one fusion partner. Such a fusion partner can e.g. facilitate

stabilization of the expression product.

For the purposes of purification, the fusion partner can

biotinylation target sequence, of BirA, flu tag, lacZ, and

signal or a targeting sequence, cf. the discussions below.

In embodiments where the modulator is itself a modulator of

and/or the V_{\max} of the relevant enzyme. A reduction in K_M re-

sults in less effectivity of the relevant enzyme insofar that

an increased substrate concentration is required to obtain 50%

of maximum activity of the enzyme. An increase of K_M has the

opposite effect. Of course, interference with an enzyme which

effects V_{\max} has as a consequence that the maximum possible rate

of activity of the enzyme is increased (when v_{\max} is increased)

or decreased (when v_{\max} is increased). At any rate, the modula-

tor of the enzyme activity will give the phenotypic impression

that the enzyme activity has either been inhibited or stimu-

lated. It is preferred in this embodiment that the modulator

is an inhibitor.

Somewhat related to this approach is the use of the methods of the present invention in screening performed on bacterial cultures used in purification processes. It is well-known in the art of e.g. waste water purification that the microbiological
5 cultures (activated sludge) which conduct the degradation of organic material, are relatively vulnerable *vis à vis* changes in the environment and therefore the provision of more robust strains of bacteria would be one way to improve such systems. Alternatively, the method of the present invention would also
10 allow for the identification/isolation of ligands and targets in such bacteria which, when interacted with, can lead to e.g. increased efficacy in degradation of specific organic or inorganic substrates.

As will be appreciated from the above, the present invention
15 therefore is highly useful in prokaryotic systems.

For the purposes of using the method of the invention in prokaryotic cells, it is preferred that the prokaryotic cells are bacteria selected from the group consisting of *Bacillus* spp. (e.g. *B. anthracis*, *B. subtilis* and *B. cereus*),
20 *Clostridium* spp. (e.g. *C. botulinum*, *C. difficile*, *C. perfringens*, and *C. tetani*), *Corynebacterium* spp. (e.g. *C. diphtheriae*, and *C. pyogenes*), *Staphylococcus* spp. (e.g. *S. aureus* and *S. albicans*), *Streptococcus* spp. (e.g. *S. pneumoniae*, *S. pyogenes*, and *S. agalactiae*), *Escherichia coli*, *Serratia*
25 *marcescens*, *Klebsiella* spp. (e.g. *K. pneumoniae*), *Proteus* spp. (e.g. *P. mirabilis*), *Citrobacter* spp. (e.g. *Citrobacter freundii*), *Salmonella* spp. (e.g. *S. typhi*, *S. typhimurium*, *S. shottmülleri* and *S. paratyphi*), *Shigella* spp. (e.g. *S. dysenteriae*, *S. flexneri*, *S. boydii*, and *S. sonnei*), *Pseudo-*
30 *monas* spp. (e.g. *P. aeruginosa*, *P. pseudomallei*, and *P. mallei*), *Acinetobacter* spp., *Aeromonas* spp., *Plesiomonas* spp., *Yersinia* spp. (e.g. *Y. pestis*, *Y. enterocolitica*, and *Y. pseudotuberculosis*), *Francisella tularensis*, *Vibrio* spp. (e.g.

V. cholerae and *V. parahaemolyticus*), *Campylobacter* spp. (e.g. *C. jejuni* and *C. coli*), *Helicobacter pylori*, *Haemophilus* spp. (e.g. *H. influenzae*, *H. parainfluenzae*, and *H. aegyptius*), *Bordetella* spp. (e.g. *B. pertussis*, *B. parapertussis*, and *B. bronchiseptica*), *Brucella* spp., *Neisseria* spp. (e.g. *N. gonorrhoeae* and *N. meningitidis*), *Treponema pallidum*, *Leptospira interrogans*; *Borrelia* spp. (e.g. *B. burgdorferi sensu stricto*, *B. garinii*, *B. afzelii*, and *B. recurrentis*), *Legionella pneumophila*, *Listeria monocytogenes*, *Mycobacterium* spp. (e.g. *M. tuberculosis*, *M. bovis*, *M. africanum*, *M. kansasii*, and *M. leprae*), *Treponema pallidum*, *Chlamydia trachomatis*, *Actinomyces* spp., *Rickettsia* spp., and *Mycoplasma* spp. (e.g. *M. pneumoniae*).

This list of bacteria thus entails bacterial families and species which are involved in pathology of a large number of diseases in humans. Of these, *E. coli* and *B. subtilis* are also used for industrial fermentation; this is also the case for lactic acid bacteria, notably *Lactococcus* spp. and *Lactobacillus* spp. and therefore it is also preferred that the inventive methods, when employed in bacterial systems, are performed on such non-pathogenic species.

When using the inventive methods in a prokaryotic system, it is very often interesting to identify those cells which are impaired in growth or lethally damaged due to the presence of the heterologous expression product introduced according to the invention. This, however, is not completely unproblematic since the main phenotypic trait associated with e.g. bacterial death is *absence* of the bacterium.

It is therefore necessary to devise an experimental setup which will allow identification of cells transformed so as to be less good survivors than other otherwise corresponding cells. One advantage is that expression of the heterologous

genetic material is under the control of an inducible promoter. In this way it is possible to expand colonies of cells which have been transformed with genetic material which, when expressed, is lethal or growth-impairing to the cells. After
 5 that, the expression can be switched on and careful examination of expanded colonies should reveal those clonal colonies which do not follow the same growth pattern as e.g. an untransformed control.

One method of doing this is to spread transformed cells on
 10 plates with growth medium and allow the cells to grow up to a pre-determined average size. The spreading of cells should be such that the visible colonies forming will generally be comprised on one single clone of cells. When the pre-determined size of colonies have been reached, all plates are blotted to
 15 a carrier medium so as to prepare a "negative" of each agar plate. After this, the expression of the inserted random sequences is induced and the colonies are allowed to grow again. The plates are examined continuously or at suitable intervals (e.g. by means of digital image processing systems
 20 well known to the skilled person). Those colonies which reveal an impaired or arrested growth compared to the remainder of the colonies or compared to controls are thereafter identified, since the growth pattern of each colony in an automated manner can be followed. These colonies can then be identified
 25 and isolated from the "negative" blot and it is thereafter a relatively simple procedure to extract the transforming genetic material and determine the sequence thereof.

In this context, one interesting option is to render antibiotic-resistant bacteria non-resistant. The growth medium
 30 either contains, or is during culturing enriched with, the antibiotic in question and the colonies which upon induction of expression can be demonstrated to be less drug resistant than controls are examined further. Also pure

bactericidal/bacteriostatic effects can be examined. In such an embodiment, the bacteria are e.g. cultured on a suitable growth medium. Those colonies which after induction of expression shows evidence of reduced or arrested growth are examined further: It is expected that some of the bacterial cells will be demonstrated to carry genetic material encoding an expression product which interacts with novel (or known) targets for antibacterial agents.

Another phenotypic trait of interest is of course superior survival of cells. It is, when dealing with utilisable bacteria, of interest to identify targets which will increase the survival rate of the bacteria. For example, bacteria used in industrial fermentations normally can be lethally damaged as a consequence of their own uncontrolled production of heterologous expression products. If genes or target molecules can be identified which have a positive effect on the survival of such bacteria, the economic potential is enormous, since a fermentation process will be rendered more economic (less need to startup of new fermentations). Similarly, bacteria used in e.g. waste water purification can be made more resistant against toxic agents in their environment.

The experimental setup in this context is relatively simple: The transformed bacteria are simply subjected to the potentially lethal condition, and only colonies which exhibit a superior survival are isolated and examined (and that will typically be the colonies which are detectable). A setup like the above-described for identifying cell death should thus not be necessary.

Finally, a large group of phenotypic traits to be examined are those which can be detected by e.g. biochemical or immunological means. It is expected that the method of the invention will allow for identification of systems in bacterial cells

which, when properly modulated, can render the bacteria more effective as producers in industrial fermentation. Such phenotypic traits could e.g. be changes in enzyme activity, changes in receptor density, changes in expression rate etc.

- 5 Special considerations apply when the randomized expression product is fused to a fusion partner which decides the final location of the expression product. Signal sequences in prokaryotes are well-known in the art, but it should briefly be mentioned that membrane-anchoring signals are known, and it is also possible to export the expression product to the periplasmic space of bacteria. Finally, it is also possible to include secretion signals so as to allow the isolation of the expression product from culture supernatant. However, in many cases it is of course most relevant to keep the expression product inside the prokaryotic cytoplasm.

Use of the method in eukaryotic systems

- It is especially preferred that the inventive method utilises eukaryotic cells as the substantially identical cells in order to allow screening for active biomolecules. Hence, these eukaryotic cells can be fungal cells, protozoan cells, animal cells, and plant cells.

- As is the case for bacteria, a number of fungi are pathogens in mammals, and therefore the present technology will, in parallel with what has been described above concerning anti-bacterial agents, be useful for identifying antifungal agents by using pathogenic fungi as the substantial identical cells in the method. Furthermore, fungi (especially yeast strains), like bacteria, are also utilised in fermentation processes (e.g. in the wine and brewing industries), and the method can therefore also be utilised using such non-pathogenic fungi as the substantially identical cells which are transformed with

30 To determine whether cells have actually incorporated foreign DNA and become transgenic, reporter genes such as GUS and Luciferase genes are used. In any case, foreign

genes must be flanked by a plant promoter in order to be expressed.

It is preferred to use cells derived from animals. These cells can be mammalian cells, arthropod cells such as insect cells, 5 avian cells, and piscine cells. A number of reasons can be listed for using such cell types which each require a relevant choice of transformation and expression systems, growth conditions, etc, all easily determined and chosen by the skilled person. It suffices to note that e.g. certain insects cause 10 enormous problems in human society (due to their direct damaging activities or due to their functions as vectors carrying infectious agents), and therefore the method of the invention would supplement in the attempts of controlling such insects. As for the mammals, birds and fish, a number of these are 15 important in agri- and aquaculture, where disease control is of interest.

According to the invention mammalian cells such as human cells/cell clones or human cell lines are most preferred. This is due to the fact that a large number of diseases in humans 20 and other mammals etiologically depend on molecular interactions in the living cell - the provision of drugs or lead compounds which interact *in vivo* with biomolecules which play a role in diseases is therefore of great interest. Preferred mammalian cells are Chinese hamster ovary (CHO) cells, VERO 25 cells, HeLa cells, W138 cells, BHK cells, COS-7 293 cells, and MDCK cells, which are all well-known in the art.

The candidate nucleic acids are hence introduced into eukaryotic cells as part of a vector to screen for modulators of target enzyme activity. By the term "introduced into" is 30 herein meant that the nucleic acids enter the cells in a manner suitable for subsequent expression of the nucleic acid. The method of introduction is largely dictated by the targeted

cell type, cf. below. Exemplary, but non-limiting methods include CaPO_4 precipitation, liposome fusion, lipofectin®, electroporation, viral infection, etc.

The randomly modified nucleic acids are preferably integrated into the host cell genome (e.g. by means of retroviral infection of the host cell), or may exist either transiently or stably in the cytoplasm (i.e. through the use of traditional plasmids utilizing standard regulatory sequences, selection markers, etc.).

Currently, the most efficient gene transfer methodologies for mammalian cells harness the capacity of engineered viruses, such as retroviruses, to bypass natural cellular barriers to exogenous nucleic acid uptake.

The vector is preferably selected from the group consisting of a retroviral vector, a vaccinia virus vector, an adenoviral vector, an adeno associated virus (AAV) vector, a herpes simplex virus (HSV) vector, an alpha virus vector, and a semliki forest virus vector.

Retroviral transduction

As many pharmaceutically important screens require human or model mammalian cell targets, retroviral vectors capable of transfecting such targets are preferred.

Therefore, the candidate nucleic acids are preferably part of a retroviral virion which infects the cells. Generally, infection of the cells is straightforward with the application of the infection-enhancing reagent polybrene. Infection can be optimized such that the cells predominantly express a single construct each, e.g. by using the ratio of virus particles to the number of cells. Alternatively, it is possible to "screen

out" cells which have been infected with more than one single virion, e.g. by quantitatively assessing a selection marker and only. The rate of infection is well-known to follow a Poisson distribution.

5 A preferred embodiment of the invention where the substantially identical cells are eukaryotic thus comprises that step (a) is carried out by

- 1) transfecting suitable packaging cells with vectors comprising the randomly modified nucleotide sequences and
10 which are integratable in virions produced by said packaging cells,
- 2) culturing said transfected packaging cells in a culture medium under conditions which facilitate production by the packaging cells of virions containing the randomly
15 modified nucleotide sequences,
- 3) recovering and optionally concentrating said virions, and
- 4) transducing said substantially identical cells with the virions.

Thus, preferably the candidate nucleic acids are introduced
20 into the substantially identical cells using retroviral vectors. The use is well-known in the art of helper-defective packaging cell-lines which are capable of producing all necessary proteins (*gag*, *pol*, and *env*) required for packaging, processing, reverse transcription, and integration of recombi-
25 nant genomes, cf. the below discussion of such cell lines.

Those RNA molecules which have in *cis* a ψ packaging signal are packaged into maturing virions. In eukaryotes, retroviruses are preferred for a number of reasons. First, their derivation is fairly easy. Second, unlike Adenovirus-mediated gene deli-
30 very, expression from retroviruses is long-term (adenoviruses do not integrate). Adeno-associated viruses have limited space for genes and regulatory units and there is some controversy as to their ability to integrate. Retroviruses therefore

currently provide the best compromise in terms of long-term expression, genomic flexibility and stable integration, among other features. The main advantage of retroviruses is that their integration into the host genome allows for their stable transmission through cell division. This ensures that in cell types which undergo multiple independent maturation steps, such as hematopoietic cell progression, the retrovirus construct will remain resident and continue to express.

Preferred retroviral vectors include vectors derived from retrovirus selected from the group consisting of Avian Leukosis-Sarcoma Virus (ALSV), Mammalian type C, Mammalian type B, and Lentivirus as well as vectors derived from MSCV (murine stem cell virus), modified MFG virus and pBABE, and optionally modified with heterologous cis-acting elements.

In general, retroviral vectors should contain as few viral sequences as possible in order to minimize potential recombination events. Only the sequences necessary for packaging, reverse transcription and integration should be retained, as well as the viral promoter, enhancer, and polyadenylation sequences.

The library of random nucleotides can be generated in a retrovirus DNA construct backbone, as is generally described in e.g. WO 97/27212. Standard oligonucleotide synthesis generates the random portion of the candidate modulator, using techniques well known in the art (cf. Eckstein, Oligonucleotides and Analogues, A Practical Approach, IRL Press At Oxford University Press, 1991); oligonucleotide libraries may be commercially purchased. Libraries with up to 10^9 unique sequences can be readily generated in such DNA backbones. After generation of the DNA library, the library is cloned into a first primer. The first primer serves as a "cassette" which is inserted into the retroviral construct. The first primer gene-

rally contains a number of elements, including for example, the required regulatory sequences (e.g. translation, transcription, promoters, etc), fusion partners and scaffold molecule(s), restriction endonuclease (cloning and subcloning) sites, stop codons (preferably in all three reading frames), regions of complementarity for second strand priming (preferably at the end of the stop codon region as minor deletions or insertions may occur in the random region), etc.

A second primer is then added, which generally consists of some or all of the complementarity region to prime the first primer and optional necessary sequences for a second unique restriction site for subcloning. DNA polymerase is added to make double-stranded oligonucleotides. The double-stranded oligonucleotides are cleaved with the appropriate subcloning restriction endonucleases and subcloned into the target retroviral vectors, described below.

In this manner the primers create a library of fragments, each containing a different random nucleotide sequence within a scaffold sequence derived from genetic material encoding a enzyme modulator. The ligation products are then transformed into bacteria, such as *E. coli* and DNA is prepared from the resulting library, as is generally outlined in Kitamura, PNAS U.S.A. 92: 9146-50 (1995), which is incorporated by reference herein.

Any number of suitable retroviral vectors may be used. Generally, the retroviral vectors may include: selectable marker genes under the control of internal ribosome entry sites (IRES), which allows for bicistronic operons and thus greatly facilitates the selection of cells expressing peptides at uniformly high levels; and promoters driving expression of a second gene, placed in sense or anti-sense relative to the 5'-LTR (long terminal repeat). Suitable selection genes include,

but are not limited to, neomycin, blastocidin, bleomycin, puromycin, and hygromycin resistance genes, as well as self-fluorescent markers such as green fluorescent protein, enzymatic markers such as *lacZ*, and surface proteins such as CD8, etc.

The retroviruses may include inducible or constitutive promoters. For example, there are situations wherein it is necessary to induce peptide expression only during certain phases of the selection process. For instance, a scheme to provide pro-inflammatory cytokines in certain instances must include induced expression of the peptides. This is because there is some expectation that over-expressed pro-inflammatory drugs might in the long-term be detrimental to cell growth. Accordingly, in this situation constitutive expression is undesirable, and the peptide is only turned on during that phase of the selection process when the phenotype is required, and then the peptide is shut down by turning off the retroviral expression to confirm the effect or ensure long-term survival of the producer cells. A large number of both inducible and constitutive promoters are known to the skilled person.

In addition, it is possible to configure a retroviral vector to allow inducible expression of retroviral inserts after integration of a single vector in target cells; importantly, the entire system is contained within the single retrovirus. Tet-inducible retroviruses have been designed incorporating the Self-Inactivating (SIN) feature of 3'LTR enhancer/promoter retroviral deletion mutant (Hoffmann *et al.*, PNAS U.S.A. 93:5185 (1996)). Expression of this vector in cells is virtually undetectable in the presence of tetracycline or other active analogues. However, in the absence of Tet, expression is turned on to maximum within 48 hours after induction, with uniform increased expression of the whole population of cells that harbour the inducible retrovirus, indicating that expres-

sion is regulated uniformly within the infected cell population. A similar, related system uses a mutated Tet DNA-binding domain such that it bound DNA in the presence of Tet, and was removed in the absence of Tet. Either of these systems is
5 suitable.

According to the present invention, the most preferred vectors (described in Example 1) are based on the murine Akv retrovirus, a mammalian type C retrovirus (NCBI taxonomy Id #11791). The Akv virus has high homology with the Moloney
10 retrovirus, commonly used in the field. A brief description of the design of these preferred vectors is as follows:

- The vectors contain a chimeric 5' LTR, allowing expression from the strong Cytomegalovirus (CMV) promoter when transcription is driven from the plasmid (as in transfections). Following integration of the vector into the host
15 genome, transcription is driven from the retroviral LTR (as in transductions).
- A versatile polylinker is present downstream of the packaging signal. This enables the insertion of peptide libraries being part of a scaffold molecule in this position.
20
- Immediately downstream of the polylinker is an internal ribosomal entry site (IRES), derived from the encephalomyocarditis (EMC) virus or an internal promoter, originating from the SV-40 virus. This allows efficient
25 translation from the downstream expression cassette either in a CAP independent (IRES), or in a CAP dependent (internal promoter) manner.
- Several different marker genes have been cloned into the
30 downstream expression cassette. For example antibiotics

resistance genes such as Neo and Hygro, fluorescent proteins such as EGFP, or surface proteins such as Δ NGFR. The availability of vectors containing different markers allows for the selection of transduced cells using either
5 drug treatment, flow cytometry or magnetic bead separation.

- Any scaffold protein or marker can be combined, either in the bicistronic vector or in a vector containing the SV-40 internal promoter.

10 In view of the above, it is hence preferred that the retroviral vector has non-identical ends so as to facilitate PCR-based generation of random DNA sequences. It is furthermore preferred that these non-identical ends contain non-identical promoters. An especially preferred retroviral vector contains
15 a heterologous promoter replacing the viral promoter in the 5'-LTR, such as a CMV promoter, an RSV promoter, an SV-40 promoter, a TK promoter, an MT promoter, or an inducible system such as Tet or Ecdysone.

Particularly well suited retroviral transfection systems
20 (packaging cells) are PE501 (US 4,861,719), Bosc23 (WO 94/19478), Ψ 2 (R. Mulligan/D. Baltimore), GP+E86 (US 5,278,056), PhoenixEco (WO 97/27212), PA317 (US 4,861,719), GP+AM12 (US 5,278,056), DA(ampho) (WO 95/10601, WO 92/05266), Bing (WO 94/19478), FLYA13 (WO 97/08330), ProPak (available
25 from SyStemix), CRIP (R. Mulligan), Ψ AM (R. Mulligan/D. Baltimore), Phoenix-Ampho (WO 97/27212), PG13 (Targeted Genetics), H9 (293GPG) (D. Ory, M Sadelain, R. Mulligan, J. Schaffer), and EcoPack (Clonetech).

Retroviral transduction is dependent upon the interaction
30 between the virus envelope glycoproteins and host cell surface receptors. By far the two most commonly exploited receptors

- for retroviral gene delivery are the ecotropic receptor (restricted to murine and rat cells) and the amphotropic receptor (widely distributed on both immortalized cell lines and on primary mammalian cells). A number of packaging cell lines, for generating either ecotropic or amphotropic viruses, exists. In addition, packaging cell lines, which pseudotype retroviral particles with either GALV (Gibbon Ape Leukemia Virus glycoprotein) or VSV G (Vesicular Stomatitis Virus G glycoprotein) have also recently been developed.
- 10 Until recently most packaging cell lines were based on NIH-3T3 cells, such as the Ψ 2 and GP+86 (ecotropic) lines and the PA317, GP+AM12 and CRIP (amphotropic) lines. These have been used extensively and work well, particularly when stable producer lines are made. However, NIH-3T3 based packaging cell
- 15 lines give relatively low titers when virus is generated from transient transfection. Over the past few years several packaging cell lines based on the highly transfectable 293 cell line (human embryonic kidney cells) have been developed. These include the Bosc23 cell line (Pear et al., 1993) an ecotropic
- 20 cell line which has been demonstrated to work very well within the boundaries of the present invention, as well as the Eco-Pack cell line from Clontech. The advantage of 293 based lines is that very high titers (up to 10^7 infectious units/ml, IU/ml) of viral supernatant can be produced from transient
- 25 transfections in as little as 48 hours. In a library situation transient transfections are preferred, as this gives all library members a chance of being equally well expressed, without any bias introduced by expression from different integration sites.
- 30 Having access to well characterised stable packaging cell lines is critical for gene therapy associated projects. For the purposes of the present invention, however, it is not necessary to employ such well defined lines, as the libraries

will always be produced from transient transfections and no stable "producer line" will or need be established. An alternative strategy for gaining entry into non-murine cells that has been explored by the present inventors is therefore to use
5 a heterologous viral envelope glycoprotein to pseudotype viruses produced in ecotropic packaging cell lines, e.g. that from Vesicular Stomatitis Virus (the VSV G protein). VSV G pseudotyping of retroviruses is interesting for two main reasons. First, the cell surface receptors for VSV G are
10 ubiquitous membrane components, such as phosphatidylserine and gangliosides. Pseudotyping with VSV G therefore confers broad tropism to the virions. Second, the VSV G protein is extremely stable once incorporated into the virions. This is important as it allows concentration of the viral supernatant by ultra-
15 centrifugation, a step which can increase the viral titers per volume unit by 10 to 100 fold.

The VSV G protein is highly fusogenic and, as a consequence, exhibits cytotoxicity in tissue culture. It has therefore not been possible to establish packaging cells that express VSV G
20 constitutively. To circumvent this problem, inducible systems have been developed (Ory et al., 1996). However, because the CellScreen™ retroviral libraries are produced from transient transfections, a very simple alternative is to transiently transfect VSV G, together with the library, into an ecotropic
25 packaging cell line, such as Bosc23. This approach allows viral supernatants of broad tropism and high titers to be produced, before severe toxicity is observed in the culture. Using this method, a panel of non-murine target cell lines have been tested for transducability and titers of up to 10⁷
30 IU/ ml of viral supernatants have routinely been achieved by the inventors.

A recently reported alternative to pseudotyping with VSV G is to pseudotype with the envelope glycoprotein of Lymphocytic

Choriomeningitis Virus (LCMV) (cf. Miletic et al., 1999, J. Virol. 73; 6114-6116). This alternative is also included as an embodiment of the present invention.

After production in packaging cells, concentration of virus
 5 may be performed as follows: Generally, retroviruses are
 titred by applying retrovirus-containing supernatant onto
 indicator cells, such as NIH-3T3 cells, and then measuring the
 percentage of cells expressing phenotypic consequences of
 infection. The concentration of the virus is determined by
 10 multiplying the percentage of cells infected by the dilution
 factor involved, and taking into account the number of target
 cells available to obtain a relative titre. If the retrovirus
 contains a reporter gene, such as *lacZ*, then infection,
 integration, and expression of the recombinant virus is mea-
 15 sured by histological staining for *lacZ* expression or by flow
 cytometry (FACS). In general, retroviral titres generated from
 even the best of the producer cells do not exceed 10^7 per ml,
 unless concentration is performed on relatively expensive or
 exotic apparatus. However, it is believed that particles as
 20 large as retrovirus will not move very far by means of brown-
 ian motion in liquid, fluid dynamics predictions show that
 much of the virus never comes in contact with the cells in
 order to initiate infection. However, if cells are grown or
 placed on a porous filter surface and retrovirus are allowed
 25 to pass the cells by gradual gravitometric flow, a high con-
 centration of virus around cells can be effectively maintained
 at all times. Thus, up to a ten-fold higher infectivity by
 infecting cells on a porous membrane and allowing retrovirus
 supernatant to flow past them has been seen. This should allow
 30 titres of 10^9 after concentration.

Upon isolation/concentration of virus, the substantially
 identical target cells are transduced by methods well-known in
 the art.

In applications when effector molecules with oncogenic potential are present in the library it is important to use retroviral supernatants which are non-infectious to humans. In these cases the ecotropic receptor can be stably introduced
 5 into the target cell of interest and viruses can be produced using ecotropic systems. The ecotropic receptor is a cationic amino acid transporter protein (mCAT), shown to be sufficient to confer susceptibility to ecotropic virus infection (Albritton et al. 1989). Expression of this receptor in a variety of
 10 human cells, including lymphocytes, have been documented in the literature (Hitoshi et al., 1998). The present inventors have demonstrated that introduction of mCAT, both by stable transfection and by transduction (using a retroviral vector encoding mCAT), yield target cells that are highly susceptible
 15 to infection by Bosc23 generated virions.

Hence, the cell lines discussed above, and the other methods for producing retrovirus, are useful for production of virus by transient transfection. The virus can be either used directly or used to infect another retroviral producer cell so
 20 as to expand the library.

Fusion partners

As mentioned above, fusion of the expression product to at least one fusion partner which facilitates expression and/or purification/isolation and/or further stabilization of the
 25 expression product is often desired.

In eukaryotes, the fusion partner is often a sorting signal or a targeting sequence. Such a sorting signal will be in the form of a signal patch or a signal peptide. The well-known function of a sorting signal is to effect export of an ex-
 30 pressed peptide into endoplasmic reticulum, into Golgi apparatus, into lysosomes, into secretory vesicles, into mitochon-

dria, into peroxisomes, or into the nucleus. Of course, also export to the membrane or out of the cell are possibilities. Preferably, the sorting signal or targeting sequence is selected from the group consisting of

- 5 - a nuclear localization signal (NLS) such as Pro-Lys-Lys-Lys-Arg-Lys-Val (SV40 large T antigen NLS), Ala-Arg-Arg-Arg-Arg-Pro (human retinoic acid receptor- β NLS), Glu-Glu-Val-Gln-Arg-Lys-Arg-Gln-Lys-Leu (NF κ B p50), Glu-Glu-Lys-Arg-Lys-Arg-Thr-Tyr-Glu (NF κ B p65), and Ala-Val-Lys-Arg-Pro-Ala-Ala-Thr-Lys-Lys-Ala-Gly-Gln-Ala-Lys-Lys-Lys-Lys-Leu-Asp (Xenopus nucleoplasmin NLS);
- 10 - a membrane anchoring sequence such as those derived from CD8, ICAM-2, IL-8, CD4, and LFA-1, and a lipidation sequence such as a myristylation or a palmitoylation sequence;
- 15 - a lysosomal sorting signal such as a lysosomal degradation sequence, and a lysosomal membrane sequence
- a mitochondrial localization sequence such as a mitochondrial matrix sequence, a mitochondrial inner membrane sequence, a mitochondrial intermembrane space sequence,
- 20 and a mitochondrial outer membrane sequence; an endoplasmic reticulum localization sequence such as the sequence from calreticulin (KDEL) and the sequence from adenovirus E3/19K protein (LULSRRSFIDEKKMP);
- 25 - a peroxisome sequence such as the peroxisome matrix sequence from Luciferase;
- a farnesylation sequence such as LNPPDESGPGCMSCKCVLS;
- a geranylgeranylation sequence such as LTEPTQPTRNQCCSN;
- a destruction sequence such as RTALGDIGN; and
- 30 - a secretory signal sequence such as the secretory signals from IL-2, growth hormone, preproinsulin, and influenza HA protein.

Enzyme modulators useful in the invention

The art has demonstrated the existence of numerous effective peptide enzyme activity modulators. Especially the enzyme inhibitors are well-characterized. Non-limiting examples which
5 are all incorporated by reference herein are listed in the following:

BPTI/Kunitz family of protease inhibitors:

- Pancreatic trypsin inhibitor (BPTI) from *Bos taurus*;
Spleen trypsin inhibitor from *Bos taurus*;
10 Inter-alpha-trypsin inhibitor light chain (bikunin) from *Bos taurus*, *Homo sapiens*, *Meriones unguiculatus*, *Mesocricetus auratus*, *Mus musculus*, *Sus scrofa*, *Pleuronectes platessa*, and *Rattus norvegicus*, respectively;
Inter-alpha-trypsin inhibitor from *Equus caballus*, *Ovis aries*,
15 and *Capra hircus*, respectively;
Hemolymph trypsin inhibitor A from *Manduca sexta*;
Hemolymph trypsin inhibitor B from *Manduca sexta*;
Colostrum trypsin inhibitor from *Bos taurus*;
Trypstatin from *Rattus norvegicus*;
20 Proteinase inhibitor from *Tachypleus tridentatus*;
Serum basic protease inhibitor from *Bos taurus*;
Chymotrypsin inhibitor SCI-III from *Bombyx mori*;
Male accessory gland serine-protease inhibitor from *Drosophila funebris*;
25 Protease inhibitor 5 II from *Anemonia sulcata*;
Chymotrypsin inhibitors SCI-I and SCI-II from *Bombyx mori*;
Proteinase inhibitors SHPI and SHPI-2 from *Stoichactis helianthus*;
Isoinhibitor K from *Helix pomatia*;
30 Trypsin inhibitor IV from *Radianthus macrodactylus*;
Venom basic protease inhibitors IX and VIIIB from *Bungarus fasciatus*;

- Venom basic protease inhibitors I and III from *Vipera ammodytes ammodytes*;
- Venom basic protease inhibitor II from *Daboia russelli siamensis*, *Hemachatus haemachatus*, and *Naja nivea*, respectively;
- 5 Venom basic protease inhibitors B and E from *Dendroaspis polylepis polylepis*;
- Venom chymotrypsin inhibitor from *Naja naja*;
- Venom basic protease inhibitors I and K from *Dendroaspis polylepis polylepis*;
- 10 Venom basic protease inhibitor K from *Dendroaspis angusticeps*
- Venom trypsin inhibitor from *Eristocophis macmahoni* and *Naja naja*, respectively;
- Protease inhibitor from *Sarcophaga bullata*;
- Tissue factor pathway inhibitor from *Homo sapiens*, *Oryctolagus*
- 15 *cuniculus*, and *Rattus norvegicus*, respectively;
- Tissue factor pathway inhibitor 2 from *Homo sapiens*;
- Uterine plasmin/trypsin inhibitor from *Sus scrofa*;
- Protease nexin II (fragment of Alzheimer's disease amyloid A4 protein) from *Homo sapiens*, *Mus musculus*, *rattus norvegicus*,
- 20 *Macaca fascicularis* and *Macaca mulatta*, respectively;
- Amyloid protein 2 from *Homo sapiens* and *Rattus norvegicus*, respectively; and
- Ornithodorin from *Ornithodoros moubata*,
- as well as inhibitors homologous therewith isolated from other
- 25 sources than those explicitly mentioned.

Serpin family of protease inhibitors:

- Alpha-1-proteinase inhibitors (alpha-1-antitrypsins) from *Equus caballus*, *Mus musculus*, *Cavia porcellus*, *Oryctolagus cuniculus*, *Bos taurus*, *Chinchilla villidera*, *Didelphis marsupiales*
- 30 *virginiana*, *Homo sapiens*, *Macropus eugenii*, *Mus caroli*, *Papio anubis*, *Sus scrofa*, *Rattus norvegicus*, and *Ovis aries*, respectively;
- Alpha-1-antichymotrypsin from *Homo sapiens*;

- Antithrombin III from *Homo sapiens*, *Bos taurus*, *Mus musculus*, *Ovis aries*, *Mesocricetus auratus*, and *Gallus gallus*, respectively;
- Alpha-2-plasmin inhibitor (alpha-2-antiplasmin) from *Bos taurus*, *Homo sapiens*, and *Mus musculus*, respectively;
- Bomapin (Protease Inhibitor 10) from *Homo sapiens*;
- Contrapsin from *Mus musculus* and *Cavia porcellus*;
- Contrapsin-like protease inhibitors from *Rattus norvegicus*;
- Factor XIIa inhibitor from *Bos taurus*;
- 10 Glia derived nexin (protease nexin I) from *Homo sapiens*, *Mus musculus*, and *Rattus norvegicus*, respectively;
- Heparin co-factor II from *Homo sapiens*, *Mus musculus*, *Oryctolagus cuniculus*, and *Rattus norvegicus*, respectively;
- 47 kDa heat shock protein (serine protease inhibitor J6) from
- 15 *Mus musculus* and *Gallus gallus*, respectively;
- C1-inhibitor from *Homo sapiens*;
- Leukocyte elastase inhibitor from *Equus caballus*, *Homo sapiens*, and *Sus scrofa*, respectively;
- Protein C inhibitor from *Homo sapiens*;
- 20 Kallistatin from *Homo sapiens*;
- Kallikrein-binding protein from *Mus musculus* and *Rattus norvegicus*, respectively;
- Maspin from *Homo sapiens*, *Mus musculus*, and *Rattus norvegicus*, respectively;
- 25 Plasminogen activator inhibitor-1 from *Bos taurus*, *Homo sapiens*, *Mus musculus*, *Mustela vison*, and *Rattus norvegicus*, respectively;
- Plasminogen activator inhibitor-2 from *Homo sapiens*, *Mus musculus*, and *Rattus norvegicus*, respectively;
- 30 Neuroserpin from *Homo sapiens*, *Mus musculus*, and *Gallus gallus*
- Cytoplasmic antiproteases 1, 2 and 3 from *Homo sapiens*
- Antitrypsin from *Bombyx mori*, respectively;
- Antichymotrypsins I and II from *Bombyx mori*;
- Alaserpin from *Manduca sexta*;

Serine protease inhibitor 2.1 from *Rattus norvegicus*;

Serine proteinase inhibitor 1 from Cowpox virus, Rabbit pox virus, Swine pox virus, Vaccinia virus, and Variola virus, respectively;

- 5 Serine proteinase inhibitor 2 from Rabbit pox virus, Vaccinia virus, and Variola virus, respectively;

Serine proteinase inhibitor 3 from Vaccinia virus and Variola virus, respectively;

Serpin 1 from Myxoma virus;

- 10 Serine proteinase inhibitor from *Halocynthia roretzi*;

Ice inhibitor from Cowpox virus (thiol-protease inhibitor);

as well as inhibitors homologous therewith isolated from other sources than those explicitly mentioned.

Kazal family of protease inhibitors:

- 15 Acrosin inhibitors from *Bos taurus*, *Homo sapiens*, *Sus scrofa*, and *Macaca fascicularis*, respectively;

Elastase inhibitor from *Anemonia sulcata*;

Ovoinhibitor from *Gallus gallus*;

Rhodniin from *Rhodnius prolixus*;

- 20 Pancreatic secretory trypsin inhibitor from *Rattus norvegicus*, *Anguilla anguilla*, *Bos taurus*, *Canis familiaris*, *Homo sapiens*, *Sus scrofa* and *Ovis aries*, respectively;

Pancreatic secretory trypsin inhibitor II from *Rattus norvegicus*;

- 25 Double-headed protease inhibitor (submandibular gland) from *Canis familiaris*, *Felis silvestris catus*, *Meles meles*, *Panthera leo*, and *Vulpes vulpes*, respectively;

Trypsin inhibitor from *Halocynthia roretzi*;

Tryptase inhibitor from *Hirudo medicinalis*;

- 30 Prostatic secretory glycoprotein from *Mus musculus* ;

Ovomucoid (third domain) from *Aburria pipile*, *Aepyodius*

arfakianus, *Afropavo congensis*, *Alectoris chukar*, *Alectoris*

rufa, *Anas platyrhynchos*, *Chloephaga picta*, *Cyanochen cyanop-*

tera, *Neochen jubata*, *Tadorna radjah*, *Lophonetta speculario-*
ides, *Anas capensis*, *Aix galericulata*, *Aix sponsa*, *Sarkidior-*
nis melanotos, *Alopochen aegyptiaca*, *Mergus cucullatus*, *Anhin-*
ga novaehollandiae, *Anser anser anser*, *Anser indicus*, *Ansera-*
 5 *nas semipalmata*, *Arborophila torqueola*, *Argusianus argus*,
Aythya americana, *Netta rufina*, *Balearica pavonina*, *Bambusi-*
cola thoracica, *Bonasa umbellus*, *Branta canadensis*, *Anser*
canagicus, *Callipepla squamata castanogastric*, *Callipepla*
squamata pallida, *Carpodacus mexicanus*, *Carpococcyx renauldi*,
 10 *Casuarus casuarus*, *Casuarus bennetti*, *Cereopsis*
novaehollandiae, *Chauna chavaria*, *Chauna torquata*, *Gallus*
gallus, *Chrysolophus amherstiae*, *Chrysolophus pictus*, *Circus*
aeruginosus, *Colinus virginianus*, *Corvus albus*, *Corvus monedu-*
la, *Coscoroba coscoroba*, *Coturnix delegorguei*, *Coturnix cotur-*
 15 *nix japonica*, *Crossoptilon crossoptilon*, *Cygnus atratus*,
Cygnus olor, *Oxyura jamaicensis*, *Oxyura vittata*, *Cyrtonyx*
montezumae, *Dacelo novaeguineae*, *Dendrocygna arborea*,
Dendrocygna arcuata, *Dendrocygna autumnalis*, *Dendrocygna*
bicolor, *Dendrocygna eytoni*, *Dendrocygna viduata*, *Dromaius*
 20 *novae-hollandiae*, *Eudromia elegans*, *Francolinus afer coqui*,
Francolinus erckelii, *Francolinus francolinus*, *Francolinus*
pondicerianus, *Fulica atra*, *Gallinula chloropus*, *Gallirallus*
australis, *Gallus varius*, *Geococcyx californianus*, *Grus*
carunculatus, *Grus japonensis*, *Grus vipio*, *Anthropoides virgo*,
 25 *Guira guira*, *Guttera pucherani*, *Gyps coprotheres*, *Polyboroides*
radiatus, *Aquila audax*, *Necrosyrtes monachus*, *Haliaeetus albi-*
cilla, *Haliastur indus*, *Larus ridibundus*, *Larus marinus*,
Vanellus spinosus, *Leipoa ocellata*, *Lophura bulweri*, *Lophortyx*
californica, *Lophortyx gambelii*, *Lophura ignita*, *Lophura*
 30 *diardi*, *Lophura leucomelana*, *Megapodius freycinet*, *Meleagris*
gallopavo, *Agriocharis ocellata*, *Nothoprocta cinerascens*,
Nothoprocta perdicaria, *Numida meleagris*, *Acryllium vultur-*
inum, *Nycticorax nycticorax*, *Opisthocomus hoazin*, *Oreortyx*
pictus, *Ortalis vetula*, *Pavo cristatus*, *Pavo muticus*, *Penelope*

jacquacu, *Penelope superciliaris*, *Perdrix perdrix*, *Phasianus colchicus colchicus*, *Phasianus versicolor*, *Phalacrocorax sulcirostris*, *Podargus strigoides*, *Polyplectron bicalcaratum*, *Polyplectron emphanum*, *Polyborus plancus*, *Pygoscelis adeliae*,
5 *Phalacrocorax albiventer*, *Rhea americana*, *Pterocnemia pennata*, *Rhynchotus rufescens*, *Rollulus roulroul*, *Scythrops novaehollandiae*, *Spheniscus humboldti*, *Struthio camelus*, *Syrmaticus mikado*, *Syrmaticus reevesii*, *Tinamus major*, *Turdus merula*, *Turnix sylvatica*, *Tympanuchus cupido*, *Centrocercus*
10 *urophasianus*, *Tragopan blythii*, *Tragopan caboti*, *Tragopan satyra*, *Tragopan temminckii*, *Lophophorus impejanus*, *Crossoptilon auritum*, *Crossoptilon mantchuricum*, *Lophura edwardsi*, *Lophura nycthemera*, *Lophura swinhoi*, *Pucrasia macrolopha*, *Catreus wallichii*, *Syrmaticus ellioti*, *Syrmaticus humiae*,
15 *Syrmaticus soemmerringii*, *Lagopus leucurus*, and *Vultur gryphus*, respectively,
as well as inhibitors homologous therewith isolated from other sources than those explicitly mentioned.

Soybean trypsin inhibitor (Kunitz) family of protease inhibitors:

20 Aspartic proteinase inhibitor from *Solanum tuberosum*;
Cathepsin D inhibitors from *Solanum tuberosum*;
Wound-induced aspartate proteinase inhibitor from *Solanum tuberosum*;
25 Chymotrypsin inhibitor 3 precursor from *Psophocarpus tetragonolobus*;
Trypsin inhibitor from *Adenanthera pavonina*;
Trypsin inhibitor from *Prosopis juliflora*;
Trypsin inhibitor from *Erythrina caffra*;
30 Trypsin inhibitor from *Erythrina latissima*;
Chymotrypsin inhibitor from *Erythrina variegata*;
Trypsin inhibitors 1A, 1B, and 2 from *Psophocarpus tetragonolobus*;

- Trypsin/chymotrypsin inhibitor from *Alocasia macrorrhiza*;
 Trypsin inhibitor from *Albizzia julibrissin*;
 Trypsin inhibitor from *Acacia confusa*;
 Trypsin inhibitors A, B and C from *Glycine max*;
 5 Trypsin inhibitors KTI1 and KTI2 from *Glycine max*;
 Latex serine proteinase inhibitor from *Carica papaya*;
 Cysteine proteinase inhibitor PCPI 8.3 from *Solanum tuberosum*;
 and
 Kunitz-type inhibitors 1 and 2 (PKI-1) from *Solanum tuberosum*,
 10 as well as inhibitors homologous therewith isolated from other
 sources than those explicitly mentioned

Potato inhibitor I family (protease inhibitors):

- Trypsin/subtilisin inhibitor from *Amaranthus caudatus*;
 Subtilisin inhibitor from *Momordica charantia*;
 15 Wound-induced proteinase inhibitor I from *Lycopersicon*
esculentum, *Lycopersicon peruvianum*, and *Solanum tuberosum*,
 respectively;
 Subtilisin inhibitors I and II from *Phaseolus angularis*;
 Proteinase inhibitor I from *Solanum tuberosum*;
 20 Chymotrypsin inhibitor 2A (CI-2A) from *Hordeum vulgare*;
 Chymotrypsin inhibitor 2B (CI-2B) from *Hordeum vulgare*;
 Chymotrypsin inhibitor 1A (CI-1A) from *Hordeum vulgare*;
 Chymotrypsin inhibitor 1B (CI-1B) from *Hordeum vulgare*;
 Chymotrypsin inhibitor 1C (CI-1C) from *Hordeum vulgare*;
 25 Chymotrypsin inhibitor I, a, b and c subunits from *Solanum*
tuberosum;
 Subtilisin inhibitor from *Vicia faba*;
 Ethylene-responsive proteinase inhibitor from *Lycopersicon*
esculentum;
 30 Proteinase inhibitors I-A and I-B from *Nicotiana tabacum*;
 Eglin C from *Hirudo medicinalis*;
 Inhibitor of trypsin and Hageman factor from *Cucurbita maxima*;
 Trypsin inhibitor MCI-3 from *Momordica charantia*; and

Trypsin inhibitor I from *Nicotiana sylvestris*, as well as inhibitors homologous therewith isolated from other sources than those explicitly mentioned.

Bowman-Birk family of protease inhibitors:

- 5 Bowman-birk type protease inhibitors from *Arachis hypogaea*, *Coix lachryma-jobi*, *Phaseolus angularis*, *Glycine max*, *Triticum aestivum*, *Arachis hypogaea*, *Phaseolus vulgaris*, *Setaria italica*, *Dolichos axillaris*, *Lonchocarpus capassa*, *Oryza sativa*, *Hordeum vulgare*, *Medicago scutellata*, *Phaseolus aureus*,
- 10 *Phaseolus lunatus*, *Vicia angustifolia*, *Vicia faba*, and *Vigna unguiculata*, respectively; and
- Wound induced trypsin inhibitors from *Medicago sativa* and *Zea mays*, respectively,
- as well as inhibitors homologous therewith isolated from other
- 15 sources than those explicitly mentioned.

Squash inhibitor family:

- Elastase inhibitor from *Momordica charantia*;
- Trypsin inhibitors I, II, and III from *Lagenaria leucantha*;
- Trypsin inhibitor I from *Citrullus vulgaris*;
- 20 Trypsin inhibitors I, III, and IV from *Cucurbita maxima*;
- Trypsin inhibitors I and II from *Luffa cylindrica*;
- Trypsin inhibitors I and II from *Momordica charantia*;
- Trypsin inhibitor I from *Momordica repens*;
- Trypsin inhibitor II from *Bryonia dioica*;
- 25 Trypsin inhibitors IIB and IV from *Cucumis sativus*;
- Trypsin inhibitor II from *Ecballium elaterium*;
- Trypsin inhibitors I, II and III from *Cucumis melo* var. *Conomon*;
- Trypsin inhibitors II and III from *Cucurbita pepo*; and
- 30 Trypsin inhibitor A from *Momordica charantia*,
- as well as inhibitors homologous therewith isolated from other
- sources than those explicitly mentioned.

Streptomyces subtilisin inhibitor (SSI) family:

Subtilisin inhibitor from *Streptomyces albogriseolus*;

Subtilisin inhibitor-like protein-1 from *Streptomyces cacaoi*;

Trypsin inhibitor STI2 from *Streptomyces longisporus*;

5 Subtilisin inhibitor-like protein-2 from *Streptomyces rochei*;

Subtilisin inhibitor-like protein-3 from *Streptomyces coelicolor*;

Subtilisin inhibitor-like protein-4 from *Streptomyces lavendulae*;

10 Subtilisin inhibitor-like protein-8 from *Streptomyces virginiae*;

Protease inhibitor SIL-V3 from *Streptoverticillium eurocidicus*;

15 Protease inhibitor SIL-V1/SIL-V4 from *Streptoverticillium flavopersicus*;

Protease inhibitor SIL-V5 from *Streptoverticillium luteovorticillatus*;

Protease inhibitor SIL-V2 from *Streptoverticillium orinoci*;

20 Alkaline protease inhibitor 2C' from *Streptomyces griseoincarnatus*;

Protease inhibitor from *Streptomyces lividans*; and

Plasminostreptin from *Streptomyces antifibrinolyticus*,

as well as inhibitors homologous therewith isolated from other sources than those explicitly mentioned.

25 ***Bombyx family of protease inhibitors***

Fungal protease inhibitor F (FPI-F) from *Bombyx mori*, as well as inhibitors homologous therewith isolated from other sources than *Bombyx mori*.

- Cystatins A, C, D, M, SN, S and SA from *Homo sapiens*;
 Cystatins B and C from *Mus musculus*;
 Cystatins C and S from *Rattus norvegicus*;
 Cystatins C from *Macaca mulatta* and *Saimiri sciureus*, respec-
 5 tively;
 Cystatin alpha (epidermal thiol proteinase inhibitor) from
Rattus norvegicus;
 Cystatin B (liver thiol proteinase inhibitor) from *Homo sapi-*
ens and *Rattus norvegicus*, respectively;
 10 Cystatin (colostrum thiol proteinase inhibitor) from *Bos*
taurus;
 Cystatins from *Gallus gallus* and *Coturnix coturnix japonica*,
 respectively;
 Cystatin from *Cyprinus carpio*;
 15 Cystatin from *Bitis arientas*;
 Cystatin I from *Zea mays*;
 Oryzacystatin-I from *Oryza sativa*;
 Oryzacystatin-II from *Oryza sativa*;
 Cystatin A from *Helianthus annuus*;
 20 Cystatin B from *Helianthus annuus*;
 Cystatin from *Vigna unguiculata*;
 Onchocystatin from *Onchocerca volvulus*;
 Cysteine proteinase inhibitor from *Solanum tuberosum*;
 Cystatin WCPI-3 from *Wisteria floribunda*;
 25 Cystatin from *Glycine max*; and
 Kininogens from *Bos taurus*, *Homo sapiens* and *Rattus norvegi-*
cus, respectively,
 as well as inhibitors homologous therewith isolated from other
 sources than those explicitly mentioned.
- 30 **Calpain family of cysteine protease inhibitors**
 Calpastatin from *Bos taurus*, *Cercopithecus aethiops*, *Homo*
sapiens, *Mus musculus*, *Sus scrofa*, *Oryctolagus cuniculus*,
Rattus norvegicus, and *Ovis aries*, respectively,

as well as inhibitors homologous therewith isolated from other sources than those explicitly mentioned.

Tissue inhibitor of metalloproteinases family

Metalloproteinase inhibitor 1 from *Bos taurus*, *Homo sapiens*,

5 *Mus musculus*, *Papio cynocephalus*, *Sus scrofa*, *Oryctolagus cuniculus*, *Rattus norvegicus*, and *Ovis aries*, respectively;

Metalloproteinase inhibitor 2 from *Bos taurus*, *Homo sapiens*, *Mus musculus*, *Rattus norvegicus*, and *Gallus gallus*, respectively; and

10 Metalloproteinase inhibitor 3 from *Bos taurus*, *Homo sapiens*, *Mus musculus*, *Rattus norvegicus*, and *Gallus gallus*, respectively,

as well as inhibitors homologous therewith isolated from other sources than those explicitly mentioned.

15 ***Carboxypeptidase A inhibitors***

Carboxypeptidase A inhibitor from *Ascaris suum*, as well as inhibitors homologous therewith isolated from other sources than *Ascaris suum*.

Metallo-carboxypeptidase inhibitors

20 Metallo-carboxypeptidase inhibitors from *Lycopersicon esculentum* and *Solanum tuberosum*, respectively, as well as inhibitors homologous therewith isolated from other sources than those explicitly mentioned.

Angiotensin-converting enzyme inhibitors

25 Angiotensin-converting enzyme inhibitor from *Thunnus albacares*;

Angiotensin-converting enzyme inhibitors from *Bothrops insularis*;

Angiotensin-converting enzyme inhibitors from *Bothrops jararaca*;

30

Angiotensin-converting enzyme inhibitor from *Agkistrodon halys blomhoffi*;

Angiotensin-converting enzyme inhibitor from *Agkistrodon halys pallas*; and

- 5 Angiotensin-converting enzyme inhibitor from *Vipera aspis*, as well as inhibitors homologous therewith isolated from other sources than those explicitly mentioned.

Protease inhibitors not belonging to a specific family

Ecotin from *Escherichia coli*;

- 10 Metalloproteinase inhibitor from *Streptomyces nigrescens*;
Proteinase inhibitor from *Erwinia chrysanthemi*;
Proteinase inhibitor from *Pseudomonas aeruginosa*;
Protease A inhibitor 3 from *Saccharomyces cerevisiae*;
Protease B inhibitors 1 and 2 from *Saccharomyces cerevisiae*;
- 15 Major pepsin inhibitor PI-3 from *Ascaris suum*;
Intracellular proteinase inhibitor from *Bacillus subtilis*;
Proteinase inhibitor PTI from *Solanum tuberosum*;
Proteinase inhibitor PCI-I from *Solanum tuberosum*;
Proteinase inhibitor IIA from *Solanum tuberosum*;
- 20 Proteinase inhibitor IIB from *Solanum tuberosum*;
Proteinase inhibitors A and B from *Sagittaria sagittifolia*;
Proteinase inhibitor from *Solanum melongena*;
Trypsin inhibitor from *Brassica napus*;
Trypsin inhibitor 2 from *Sinapis alba*;
- 25 Trypsin inhibitor from *Zea mays*;
Trypsin inhibitor from *Sinapis arvensis*;
Trypsin inhibitor from *Trichosanthes kirilowii*;
Wound-induced proteinase inhibitor II from *Lycopersicon esculentum*;
- 30 Protease inhibitors LCMI I and PMP-D2 from *Locusta migratoria*;
Protease inhibitor from *Bacillus brevis*;
Marinostatins C-1, C-2 and D from *Alteromonas* sp.; and
Host protease inhibitor from bacteriophage T4,

as well as inhibitors homologous therewith isolated from other sources than those explicitly mentioned.

Cereal alpha-amylase/trypsin inhibitor family

- Alpha amylase/trypsin inhibitor CM1 from *Triticum aestivum*;
- 5 Alpha amylase/trypsin inhibitor CM2 from *Triticum aestivum*;
- Alpha amylase/trypsin inhibitor CM3 from *Triticum aestivum*;
- Alpha amylase/trypsin inhibitor CM16 from *Triticum aestivum*;
- Alpha amylase/trypsin inhibitor CM17 from *Triticum aestivum*;
- Alpha amylase inhibitor 0.19 from *Triticum aestivum*;
- 10 Alpha amylase inhibitor 0.28 from *Triticum aestivum*;
- Alpha amylase inhibitor 0.53 from *Triticum aestivum*;
- Alpha amylase inhibitor WDAI-3 from *Triticum aestivum*;
- Alpha amylase/trypsin inhibitor CMA from *Hordeum vulgare*;
- Alpha amylase/trypsin inhibitor CMB from *Hordeum vulgare*;
- 15 Alpha amylase/trypsin inhibitor CMC from *Hordeum vulgare*;
- Alpha amylase/trypsin inhibitor CMD from *Hordeum vulgare*;
- Alpha amylase inhibitor CME from *Hordeum vulgare*;
- Alpha amylase inhibitor BMAI-1 from *Hordeum vulgare*;
- Alpha amylase inhibitor BDAI-1 from *Hordeum vulgare*;
- 20 Alpha amylase/trypsin inhibitor from *Eleusine coracana*; and
- Trypsin/factor XIIa inhibitor from *Zea mays*,
- as well as inhibitors homologous therewith isolated from other sources than those explicitly mentioned.

Alpha-amylase/trypsin inhibitor homologous to thaumatin

- 25 Alpha-amylase/trypsin inhibitor from *Zea mays* as well as
- inhibitors homologous therewith isolated from other sources
- than *Zea mays*.

Alpha-amylase/subtilisin inhibitor family

- Alpha-amylase/subtilisin inhibitor from *Hordeum vulgare*;
- 30 Alpha-amylase/subtilisin inhibitor from *Triticum aestivum*; and
- Alpha-amylase/subtilisin inhibitor from *Oryzae sativa*,

as well as inhibitors homologous therewith isolated from other sources than those explicitly mentioned.

Inhibitors of insect alpha-amylases

Small protein inhibitor of insect alpha-amylases 1, 2 and 3
5 from *Sorghum bicolor milo* as well as inhibitors homologous therewith isolated from other sources than *Sorghum bicolor milo*.

Inhibitors of mammalian alpha-amylases derived from Streptomyces species

10 Alpha-amylase inhibitor HAIM I from *Streptomyces griseosporus*;

Alpha-amylase inhibitor PAIM I from *Streptomyces olivaceoviridis*;

15 Alpha-amylase inhibitor HAIM II from *Streptomyces griseosporus*;

Alpha-amylase inhibitor PAIM II from *Streptomyces olivaceoviridis*;

Alpha-amylase inhibitor AI-3688 from *Streptomyces aureofaciens*;

20 Alpha-amylase inhibitor Z-2685 from *Streptomyces rochei*; and Alpha-amylase inhibitor HOE-467A from *Streptomyces tendae*, as well as inhibitors homologous therewith isolated from other sources than those explicitly mentioned.

Trehalase inhibitors

25 Trehalase inhibitor from *Periplaneta americana* as well as inhibitors homologous therewith isolated from other sources.

Polygalacturonase inhibitors

Polygalacturonase inhibitors from *Phaseolus vulgaris* and *Pyrus communis* as well as inhibitors homologous therewith isolated
30 from other sources than those explicitly mentioned.

Fucosyltransferase inhibitors

Fuctinins from *Rattus norvegicus* as well as inhibitors homologous therewith isolated from other sources.

Protein kinase C inhibitors

- 5 14-3-3 Protein beta/alpha from *Bos taurus*, *Ovis aries*, *Homo sapiens*, and *Rattus norvegicus*, respectively;
- 14-3-3 Protein epsilon from *Mus musculus*, *Ovis aries*, *Homo sapiens*, and *Rattus norvegicus*, respectively;
- 14-3-3 Protein eta from *Bos taurus*, *Mus musculus*, and *Rattus*
10 *norvegicus*, respectively;
- 14-3-3 Protein gamma from *Bos taurus*, *Ovis aries*, and *Rattus norvegicus*, respectively;
- 14-3-3 Protein zeta/delta from *Bos taurus*, *Mus musculus*, *Ovis aries*, *Homo sapiens*, and *Rattus norvegicus*, respectively;
- 15 Hint protein from *Bos taurus*, *Rattus norvegicus*, *Homo sapiens*, *Mus musculus*, and *Oryctolagus cuniculus*, respectively; and
- 14 kDa zinc-binding protein from *Brassica juncea* and *Zea mays*, respectively,
- as well as inhibitors homologous therewith isolated from other
20 sources than those explicitly mentioned.

cAMP-dependent protein kinase inhibitors

- cAMP-dependent protein kinase inhibitor (muscle/brain form) from *Homo sapiens*, *Oryctolagus cuniculus*, *Mus musculus*, and *Rattus norvegicus*, respectively, and
- 25 cAMP-dependent protein kinase inhibitor (testis form) from *Mus musculus*, and *Rattus norvegicus*, respectively,
- as well as inhibitors homologous therewith isolated from other sources than those explicitly mentioned.

Cyclic nucleotide phosphodiesterase inhibitor

Cyclic nucleotide phosphodiesterase inhibitor from *Dictyostelium discoideum* as well as inhibitors homologous therewith isolated from other sources.

5 Protein phosphatase inhibitors

Protein phosphatase inhibitor 1 from *Homo sapiens*, *Oryctolagus cuniculus*, and *Rattus norvegicus*, respectively;

Protein phosphatase inhibitor 2 from *Homo sapiens*, *Oryctolagus cuniculus*, and *Rattus norvegicus*, respectively;

- 10 Heat-stable protein phosphatase 2a inhibitor I1PP2A from *Bos taurus* and *Homo sapiens*, respectively; and
Phosphatase RAPA inhibitor from *Bacillus subtilis*,
as well as inhibitors homologous therewith isolated from other sources than those explicitly mentioned.

15 TCD/MRS6 family of GDP dissociation inhibitors

Secretory pathway GDP dissociation inhibitor from *Saccharomyces cerevisiae*;

Rab GDP dissociation inhibitor alpha from *Bos taurus*, *Homo sapiens*, *Mus musculus*, and *Rattus norvegicus*, respectively;

- 20 Rab GDP dissociation inhibitor beta from *Homo sapiens*, *Mus musculus*, and *Rattus norvegicus*, respectively;
Rho GDP-dissociation inhibitor 1 from *Bos taurus*, *Homo sapiens*, *Caenorhabditis elegans* and *Cavia porcellus*, respectively;
Rho GDP-dissociation inhibitor from *Saccharomyces cerevisiae* ;
25 Rho GDP-dissociation inhibitor 2 from *Homo sapiens* and *Mus musculus*, respectively; and
Rho GDP-dissociation inhibitor from *Mus musculus*,
as well as inhibitors homologous therewith isolated from other sources than those explicitly mentioned.

ATPase inhibitors

Mitochondrial ATPase inhibitors from *Bos taurus*, *Caenorhabditis elegans*, *Pichia jadinii*, *Sus scrofa*, *Rattus norvegicus*, and *Saccharomyces cerevisiae*, respectively, and

- 5 Sodium/potassium ATPase inhibitor from *Sus scrofa*, as well as inhibitors homologous therewith isolated from other sources than those explicitly mentioned.

Phospholipase A2 inhibitory proteins

- Annexin I from *Bos taurus*, *Homo sapiens*, *Mus musculus*, *Sus*
10 *scrofa*, *Rattus norvegicus*, *Oryctolagus cuniculus*, *Cavia cutleri*, *Gallus gallus*, and *Columba livia*, respectively;

Annexin III from *Homo sapiens* and *Rattus norvegicus*, respectively;

- Annexin V from *Homo sapiens*, *Mus musculus*, *Rattus norvegicus*,
15 and *Gallus gallus*, respectively;

Uteroglobulin from *Oryctolagus cuniculus* and *Lepus capensis*, respectively; and

- Phospholipase A2 inhibitor from *Trimeresurus flavoviridis*, as well as inhibitors homologous therewith isolated from other
20 sources than those explicitly mentioned.

Ribonuclease inhibitors

Barstar from *Bacillus amyloliquefaciens*;

- Ribonuclease inhibitor from *Homo sapiens*, *Sus scrofa*, and *Rattus norvegicus*, respectively, as well as inhibitors homologous therewith isolated from other sources than those
25 explicitly mentioned.

RNA polymerase inhibitors

- Bacterial RNA polymerase inhibitors from Bacteriophages T3 and T7 as well as inhibitors homologous therewith isolated from
30 other sources.

DNA-entry nuclease inhibitors

Competence protein J from *Bacillus subtilis* as well as inhibitors homologous therewith isolated from other sources.

Beta-lactamase inhibitors

- 5 Beta-lactamase inhibitor from *Streptomyces clavuligerus* as well as inhibitors homologous therewith isolated from other sources.

To this list of enzyme inhibitors can be added functionally related inhibitors such as the inhibitor of calcium transport
10 seminalplasmin from *Bos taurus* and *Mus musculus*, respectively, as well as inhibitors homologous therewith isolated from other sources.

To the above list of suitable scaffold molecules to be used in the invention should be added other agents having an effect on
15 the activity of enzymes. One interesting candidate is thioredoxin.

All of the above-listed scaffold molecules can be substituted with an effective part of the complete molecule.

Properties of the scaffold molecule

- 20 Since the peptide library presumably can reach every compartment of a cell, it is beneficial if the scaffold enzyme inhibitor protein is not too large, and that it is stable towards e.g. proteolytic attack and insensitive to the reducing environment inside eukaryotic cells. Hence, its function
25 should preferably not be dependent on the formation of disulfide bridges, since these are not formed in the cytosol or nucleus of such cells. In addition the scaffold protein should contain one or more exposed loops in which peptides can be inserted without markedly changing the structure or stability

CI-2A was originally purified from the endosperm of the high-lysine barley Hiproly and shown to be a tight binding inhibitor of the microbial subtilisins Carlsberg and Novo as well as of chymotrypsin. The N-terminal amino acid residue in CI-2A has a blocked amino group as direct amino acid sequencing was unsuccessful. However, most of the amino acid sequence of CI-2A has been determined at the protein level. In addition, it was shown that CI-2A purified from barley is N-terminally processed either during synthesis and storage in the endosperm or in the process of purification. The absence of the 17 N-terminal amino acid residues does not influence the complex formation of CI-2A with subtilisins. Combining the results of amino acid sequencing and cDNA sequencing it has been deduced that CI-2A consists of 83 amino acid residues in a single polypeptide chain containing no disulfide bonds. The blocked N-terminal amino acid residue is serine. The reactive site in CI-2A has been determined to be the Met59-Glu60 peptide bond and the residues in the region Ile56-Arg62 have been demonstrated to be involved in the intermolecular contacts between inhibitor and protease.

The three-dimensional structures of uncomplexed CI-2A as well as of CI-2A complexed with subtilisin Novo are known from X-ray crystallography. The three-dimensional structure of CI-2A has also been determined using NMR spectroscopy, revealing that the reactive loop of CI-2A is dynamic. CI-2A consists of a single α -helix docking against four β -strands. The surface loop stretches across the free side of the sheet and is composed of eight residues: Gly54-Tyr61. In contrast to most enzyme inhibitors, CI-2A lacks disulfide bonds as well as glycosylation sites. In the structures determined, only the 64 C-terminal amino acid residues are defined (L20-G83); this truncated version retains the functionality of the native protein. Comparing the complexed form with the two uncomplexed forms of CI-2A reveals few differences. The most notable

difference is that the reactive site loop seems to have a less ordered structure in the uncomplexed forms than in the complexed form. The three-dimensional structure of CI-2A in complex with subtilisin Novo has also been compared to the three-dimensional structure of eglin C in complex with subtilisin Carlsberg. The two homologous inhibitors have highly similar secondary and tertiary structures.

Recombinant variants of N-terminally truncated CI-2A (CI-2A(L20-G83)) and CI-2A with an N-terminal Asp-Pro extension have been widely used to study the folding and stability of CI-2A. The structure of CI-2A in complex with subtilisin Novo has revealed that the number of intermolecular contacts between inhibitor and protease in the P4-P1 region (Ile56-Met59) of the inhibitor are much larger than in the P1'-P3' region (Glu60-Arg62).

Further aspects of the invention

Having identified a modulator according to the above-detailed methods of the invention it is normally of interest to provide large quantities thereof for the purposes of further research and development, including possible identification of the target molecule with which the modulator physically interacts.

Therefore, the invention also pertains to a method for the preparation of a replicable expression vector, the method comprising the steps of identifying a modulator by the methods of the invention, and subsequently

- isolating or synthesizing a nucleic acid sequence which encodes the modulator, and
- engineering a replicable expression vector comprising an operon which comprises, in the 5'-3' direction and in operable linkage, 1) a promoter for driving expression of the nucleic acid sequence, 2) optionally a nucleotide

sequence encoding a leader peptide, 3) the nucleic acid sequence, and 4) a termination signal.

Such methods are widely known in the field of genetic engineering and molecular biology. The skilled person will find suitable guidance in e.g. Sambrook J, Fritsch EF, Maniatis T. 1989. "Molecular cloning: A laboratory manual", 2nd ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.

In this part of the invention it is preferred that the promoter is inducible; constitutive promoters are not excluded though. Depending on the choice of host cell to carry and express the vector, the promoter is selected from the group consisting of a bacterial promoter, a fungal promoter such as a yeast promoter, and a mammalian promoter. The vector can be in the form of a plasmid, a phage, a cosmid, a minichromosome, or a virus, again depending on choice of host cell and other considerations applying for the specific case. However, it is most preferred that the expression vector is capable of being integrated into the genome of a suitable host cell, since the expression therein will then be more stable over time than is the case with non-chromosomal transformation of the host cell.

Well-known vector systems are based on bacterial plasmid pBR322, λ -phage, and yeast plasmid YRp7, but other suitable and feasible choices are known to the skilled person.

After having provided a suitable expression vector as outlined above, it is preferred that the modulator is produced by transforming a suitable host cell with an expression vector prepared as described above. Such a host cell can be bacterial (e.g. *E. coli*, *Bacillus subtilis*, or any other suitable bacterial host cell), a fungus (e.g. a yeast cell such as *Saccharomyces cerevisiae* or *Picchia pastoris*) or a plant, insect or mammalian cell (which can be any of the above-dis-

cussed cells or cell-types suitable for use as the "substantially identical cells" in the method of the invention).

After having provided a producer cell line as described above it is now possible to produce the modulator of the invention
 5 by growing the transformed cell prepared as described above in a culture medium under conditions which facilitates expression by the cell of the randomly modified nucleotide sequence, and subsequently harvesting the expression product from the cell and/or the culture medium. Alternatively, the modulator can be
 10 produced by synthesizing the modulator by means of chemical synthesis on the basis of the sequence determined in step (e). In the case that the modulator is a peptide, the well-known techniques of solid- or liquid-phase peptide synthesis can be employed and also if the modulator is a ribonucleic acid, methods for synthetic production thereof are readily available.
 15

An important part of the invention pertains to the isolation/identification of the target biomolecules which are engaging the modulator, the identification, isolation and production of which is described above. Hence an important part of
 20 the invention pertains to a method for isolating and/or identifying a target biomolecule, the method comprising providing a modulator according to the methods described herein and subsequently using the modulator as an affinity ligand in an affinity purification step so as to isolate the target
 25 biomolecule from a suitable sample. The affinity purification step can e.g. be an affinity chromatographic step, an affinity mass spectrometry step, or a co-immunoprecipitation step. However, any suitable method for affinity-based isolation/purification can be employed.

30 Alternatively, the modulator can be used as a probe against a cDNA library derived from the substantially identical cells or

as bait in a two- or three-hybrid system (bacterial, fungal or mammalian).

It is preferred that the target biomolecule is a peptide or a nucleic acid, since this also allows for sequence determination thereof.

The potential use of such a target biomolecule is to employ it in a drug-development program. For this purpose it is often useful to resolve or get information about the 3-dimensional structure of the target biomolecule (by means of methods available, e.g. X-ray diffraction studies, NMR analysis, circular dichroism, etc).

Having isolated a target biomolecule as described above, the invention allows for the rational selection of a chemical compound to be used as a putative drug candidate in drug development, the method comprising the steps of

- assaying a library of chemical compounds for interaction with a target biomolecule which has been *de novo* isolated according to the methods of the invention, and
- selecting compounds which interact significantly with the target biomolecule.

Such an identified drug candidate can be a lead compound or a drug candidate as such. A "lead compound" is in the present application understood as being a compound which is not in itself suitable as a drug but which exhibits a number of characteristics which are interesting when viewed from the point of view of medical therapy. The reason such a lead compound is unsuitable could be toxicity, unsuitable pharmacokinetic or pharmacodynamic properties, difficulties relating to preparation and purification etc. In such cases, the lead compound is used as a model for *de novo* synthesis of

other chemical compounds which are designed so as to be related to the active part of the lead compound in 3D structure and distribution of charged, polar and non-polar groups.

This approach can be refined by initially identifying the members of the library by methods of structure-based or non-structure based computer drug-modelling. Suitable non-structure based methods are disclosed in US 5,307,287 and US 5,025,388; a method known as CoMFA). An alternative is HASL (Hypothetical Active Site Lattice; Hypothesis Software). Both these methods are based on 3D-QSAR. A feasible structure-based approach is e.g. disclosed in WO 95/06293.

Finally, a very important part of the present invention pertains to a method for the preparation of a medicinal product, the method comprising the steps of

- 15 a) selecting a chemical compound by the methods of the invention described above,
- b) performing pre-clinical tests with the chemical compound in order to assess the suitability thereof as a medicinal product,
- 20 c) entering, if the chemical compound is deemed suitable in step (b), clinical trials using the chemical compound in order to obtain market authorization for a medicinal product including the chemical compound as a pharmaceutically active substance, and
- 25 d) upon grant of a market authorization, admixing the chemical compound with a pharmaceutically acceptable carrier, excipient or diluent and marketing the thus obtained medicinal product.

In other words, also encompassed by the present invention is a method for developing a medicinal product, the method comprising that a modulator identified according to the method of the invention serves as a lead compound in the development

phase or wherein a target biomolecule isolated/identified according the invention serves as an interaction probe against putative drug candidates in the drug discovery phase.

The above-outlined methods should of course take into consideration all necessary requirements in order to meet GCP and GMP standards. At any rate, this method is completely depending on the initial provision of the modulator identified according to the invention.

LEGEND TO THE FIGURES

10 Fig. 1: A schematic representation of pCMVbipep/CI-2A with the functional *cis*-elements found in pCMVbipep indicated. At the top, a schematic representation of pCMVbipep is presented and the CI-2A cDNA region is expanded in the illustrations below showing the position of the various signal peptides (SEQ ID NOs: 35-37) present in pCMVbipepER/CI-2A, 15 pCMVbipepNLS/CI-2A, and pCMVbipepSL/CI-2A, respectively. The extra amino acids added to CI-2A are written in one letter code with the essential amino acid sequences required for function underlined. Abbreviations: nuclear localization 20 signal, NLS; endoplasmic reticulum, ER; secretoric leader, SL; retention signal, RS.

Fig. 2: Total extracts from CMVbipep/CI-2A transduced cells are capable of inhibiting the protease activity of subtilisin. Subtilisin was incubated with increasing amounts of extracts 25 from the indicated cell lines either transduced with CMVbipep (NIH-3T3, U2OSmCAT, and 293mCAT) or CMVbipep/CI-2A (NIH-3T3/CI-2A, U2OSmCat/CI-2A, and 293mCat/CI-2A) and subsequently assayed for residual proteolytic activity. Each reaction with a given extract concentration was determined in triplicate and 30 the shown velocities are based on the mean values.

Fig. 3: Nuclear extract from CMVbipepNLS/CI-2A, but not from CMVbipep/CI-2A transduced NIH-3T3 cells exerts CI-2A activity.

A) Subtilisin was incubated with either 2 or 10 μ l of nuclear extract from NIH-3T3 cells transduced with either CMVbipep
5 (-), CMVbipep/CI-2A (CI-2A), or CMVbipepNLS/CI-2A (NLS/CI-2A) and subsequently assayed for proteolytic activity.

B) As for A except that 0.4 or 2 μ l total cell extract was used. Each reaction with a given extract concentration was determined in triplicate and the shown velocities are based on
10 the mean values.

Fig. 4: Schematic presentation of pFAB60 constructs.

Upper panel: pFAB60/CI-20 contains the truncated version of CI-2A is inserted in frame with a pelB leader sequence at the 5' end and the deleted gene encoding a fragment of the M13
15 phage surface protein III (Δ gIII) at the 3'end. The pelB leader directs the expressed fusion protein to the bacterial membrane thereby facilitating incorporation of the CI-2A/ Δ pIII fusion protein into phage particles.

Middle panel: pFAB60/muCI-2A contains the CI-2A cDNA including
20 the recognition sites for *Mun*II and *Sal*I restriction enzymes.

Lower panel: pFAB60/muCI-2A_rc has amino acid 58-61 substituted for the underlined 19 randomly composed amino acids (SEQ ID NO: 38, residues 2-20). The amino acids are shown in one letter codes and the numbers refers to the unmodified CI-2A
25 amino acid sequence (cf. The numbering in SEQ ID NO: 2).

Fig. 5: CI-2A and CI-2A_rc can be displayed on the surface of phage particles.

Anti CI-2A antibodies were immobilized and incubated with 0 or 5×10^{11} phage particles, produced and purified as in Johansen
30 et al., 1995, Protein Eng. 10, pp. 1063-1067 and quantified by OD269 measurement. CI-2A negative (-) CI-2A or CI-2A_rc carrying phage particles were used. The retained phage particles were finally detected by a horse radish peroxidase conjugated

anti phage antibody. The results shown are mean values from 4 independent measurements with indicated standard deviation.

Fig. 6: Construction of a CI-2A presented library using the *MunI* and *SalI* cloning sites.

- 5 A) A degenerated oligo (SEQ ID NO: 33, residues 21-46) covering the recognition sites for *MunI* and *SalI* is converted to a double stranded form in a single extension reaction.
- B) Schematic presentation of the modified cDNA of a CI-2A peptide library.
- 10 C) Three-dimensional structure of the 64 C-terminal amino acids. The substituted amino acids are shown in white with the sequence of the randomized CI-2A gene above.

Fig. 7: Construction of a CI-2A presented library using *BamHI* and *SalI* cloning site.

- 15 A) The 5' part of the CI-2A cDNA can be made by using overlapping oligos that after annealing are extended by the use of a DNA polymerase. The resultant fragment can then be cleaved with *BamHI* and *SalI* before ligation into pCMVbi pep/muCI-2A.
- B) Another strategy is to use the randomized oligo in a PCR
- 20 together with an upstream forward primer. Again a *BamHI/SalI* fragment can be purified and ligated into pCMVbi pep/muCI-2A.

PREAMBLE TO EXAMPLES

In the following, the present invention is illustrated by way of example wherein CI-2A is used as starting point for the

25 CellScreen™ technique adapted according to the invention so as to allow intracellular expression of a scaffold protein inhibitor which is randomly modified in the active site. This example is non-limiting, in the sense that other suitable protein inhibitors of enzymes could be used instead of CI-2A.

30 The skilled person can readily perform the necessary substitu-

The 5788 bp hybrid plasmid pCMVbipep (the sequence of which is set forth in SEQ ID NO: 39 and which is shown schematically in Fig. 1 with CI-2A inserted downstream the packaging signal) consists of an AKV derived retroviral insert which has been cloned into the pUC-19 cloning vector. The retroviral insert contains a chimeric 5' LTR, allowing expression from the strong cytomegalovirus (CMV) promoter when transcription is driven from the plasmid. Following integration of the vector into a host genome, transcription is driven from the retroviral LTR. A versatile poly-linker is present downstream of the packaging signal. This enables the insertion of peptide libraries in this position. Immediately downstream of the polylinker is an internal ribosomal entry site (IRES), derived from the encephalomyocarditis (EMC) virus (Koo et al. 1992, figure 2A-G). This allows efficient translation from the downstream expression cassette in a CAP independent (IRES). A Neo marker gene is found in the downstream expression cassette.

pCMVbipep includes a chimeric CMV and Akv promotor/enhancer. It was constructed from the vector plasmid constructs PUT 649 (CAYLA, toulouse FRANCE) and AkvBiPep (Duch et al., unpublished, described below). AkvBiPep was digested with *EcoRI* and *AscI* and the 2779 bp fragment from position 3293 through 5670 to 401 was isolated and ligated to a 543 bp fragment contain-

ing the enhancer/promotor of CMV position 44 to 548. This fragment was obtained by PCR amplifying an *EcoRI* and *AscI* digest of PUT 649 using the following two primers

GGTCAGGAATTCTCCGGAATTGGCTAGCCTAGAGTCCGTTACATAACT (SEQ ID NO:

5 40) and

GAGGACTGGCGCGCCGAGTGTGGGGTTCTTACCCTTTTTATAGACCTCCCACCGTACACGCT (SEQ ID NO: 41). The resulting fragment was digested with *AscI* and ligated to an *AscI* fragment of AkvBiPep (fragment from position 828 to 3293).

10 AkvBiPep was constructed by digesting pBiZeo-Neo (Duch et al., Biotechniques, 1999, **26**(6): 1032-4, 1036) with *BamHI* and *StuI*. The fragment from 1708 through 6054 to 1240 was ligated to a DNA fragment made by extending with two oligonucleotides. The oligonucleotides were

15 AGATCTCCGAGGCCTGGGACCCTTCGAATTCGTTAACTGATCAACGCGTTCTAGACTACATG GCGGCCGCGTGTTT (SEQ ID NO: 42) and

GGGGGATCCAGAGCTCGAGCTTTGAAAAACACGCGGCCGCCATG (SEQ ID NO: 43).

After extension and prior to ligation, the DNA fragment was digested with *BamHI* and *StuI*. This operation removes the Zeo

20 gene in pBiZeo-neo and replaces them with a polylinker.

To construct pCMVbipep/CI-2A, 2 µg pCMVbipep was digested with *BamHI*/*XhoI* as described in A-5. The 5778 base pair fragment was subsequently purified from a 0.8% agarose gel according to A-7. A CI-2A cDNA fragment encoding amino acids 21-83 (cf. the amino acid numbering in SEQ ID NO: 2) of wild type CI-2A protein fused to an in frame methionine start codon was amplified by PCR from a pUC 19 derived plasmid containing a fragment encoding the wild type CI-2A protein (cf. the nucleotide numbering in SEQ ID NO: 1) (Generous gift from Dr. Ib G.

30 Clausen, Novo Nordic A/S, Denmark) - the cDNA fragment includes the nucleotide sequence of SEQ ID NO: 1, where nucleotides 249, 252, and 279 are T, C, and T, respectively. The PCR conditions in the 4 performed reactions were as described in

A-3 using the following primers CGGGATCCATGAAGACAGTGGCCAGAG (SEQ ID NO: 3) and CGCTCGAGTCAGCCGACCCTGGGGACCT (SEQ ID NO: 4) which flank the specified region of CI-2A with recognition sites for *Bam*HI and *Xho*I. The reaction mixture was applied to 15 three-step cycles of 94°C for 1 minute, 60°C for 30 seconds, 72°C for 30 seconds followed by purification of the amplified DNA fragment as described in A-3 with a 100 µl elution volume. The purified DNA fragment was then digested (see section A-5) and purified (see section A-7) using 40 10 units of *Bam*HI and *Xho*I with 120 µl as final reaction volume. This fragment was ligated into the *Bam*HI/*Xho*I cleaved pCMVbipep (see section A-1) and confirmed by DNA sequencing (section A-8) using the pCMVbipep specific primer CTGTATCTGGCGGCTCCGTGG (SEQ ID NO: 5).

15 1-b: Construction of pmCATIREShyg

To enable transduction of non-murine cells with retroviral vectors harvested from the Bosc packaging cell line a vector (pmCATIREShyg) encoding the ecotropic receptor was constructed. The mCAT cDNA was obtained from pJET (Albritton et al. 20 (1989) Cell **57**, pp 659-666) and inserted into the pIRESHhyg (CloneTech) to give rise to pmCATIREShyg. This was done by digesting pJET in 1 x *Eco*RI restriction enzyme buffer together with 2 units/µl *Eco*RI (see section A-5). The 5' overhangs of the *Eco*RI digestion were filled out using Klenow polymerase 25 according to the manufacturer's protocol (New England Biolabs). After incubation for 1 hour the sample was purified by phenol/CHCl₃ extraction (see section A-4) followed by digestion with 20 units *Bam*HI in a reaction volume of 20 µl (see section A-6) and purified on a 1.0% agarose gel (see section A-7). 30 This fragment was ligated into the 5699 base pair *Bam*HI/*Bst*XI fragment of pIRESHhyg prepared as the mCAT fragment except that the blunt ended termini were derived from the *Bst*XI site. After ligation and transformation, positive clones events were isolated and confirmed by DNA sequencing (section A-9) using

the following primers ACAGCTGGCCCTCGCAGAC (SEQ ID NO: 6),
 CCCACTGCTTACTGGCTTAT (SEQ ID NO: 7), TGGGGCTGCACGTCATTTG (SEQ
 ID NO: 8), TGTGCTACGGCGAGTTTGGT (SEQ ID NO: 9),
 GGTTCGTGAAAGGCTCCATT (SEQ ID NO: 10), and
 5 GAAATGTTTACAATTAGCCCTG (SEQ ID NO: 11).

1-c: Construction of pCMVbipepNLS/CI-2A

An oligonucleotide encoding the SV-40 large T antigen nuclear
 localization signal was added in frame to the N-terminus of
 the truncated CI-2A version situated in pCMVbipep/CI-2A (Fig.
 10 1). The construction was performed by PCR (see section A-2)
 using 25 pmol of
 GAAGATCTATGGCGGCCGCACCAAAAAAGAAGAGAAAGGTAGGATCCATGAAGACAGAGT
 (SEQ ID NO: 12) and CGCTCGAGTCAGCCGACCCTGGGGACCT (SEQ ID NO:
 13) as primers and pCMVbipep/CI-2A as template. This reaction
 15 was performed in duplicate and applied to 25 cycles consisting
 of 94°C for 1 min, 45°C for 1 minute, 72°C 1 minute. The
 solution was ethanol precipitated before purification of the
 250 base pair DNA fragment using a 2% agarose gel (see section
 A-7). The termini of the fragment were trimmed by addition of
 20 20 units of *Bgl*III and *Xho*I and 6 µl NEBuffer 3 to a 60 µl
 reaction volume (see section A-6) including 1 mg/ml bovine
 serum albumine (New England Biolabs). The cleavage products
 were separated on a 2% agarose gel and the 240 base pair
 fragment was subsequently purified (see section A-7) with a 50
 25 µl elution volume. This fragment was finally ligated into
*Bam*HI/*Xho*I cleaved pCMVbipep (see construction of
 pCMVbipep/CI-2A) and confirmed by DNA sequencing (see A-8).

1-d: Construction of pCMVbipepSL/CI-2A and pCMVbipepER/CI-2A

The secretoric leader (SL) was amplified by PCR using
 30 pBapePuro containing the human immunoglobulin heavy chain
 signal peptide (Beerli et al. (1994) J. Biol. Chem. 269,
 pp23931-23936) as template and 25 pmol of
 GAAGATCTATGGACTGGATCTGGCGCATCC (SEQ ID NO: 14) and

GAGGATCCAGAATGAGCGCCGGTAGCAG (SEQ ID NO: 15) as primers. The reaction conditions were similar to those described in construction of pCMVbipepNLS/CI-2A. The amplified 74 base pair product was after phenol/CHCl₃ extraction (see section A-4) 5 digested with *Bam*HI and *Bgl*II as described in section A-5 except that the reaction included 1 µl/ml bovine serum albumin (New England Biolabs). After digestion, the 68 base pair fragment was purified using a 3% low melting agarose gel (see section A-6) ending up with a 30 µl volume. A *Bam*HI digested 10 pCMVbipep/CI-2A vector was prepared essentially as described for construction of pCMVbipep/CI-2A except that 10 units of calf intestinal phosphatase (Boehringer Mannheim) were present during the last hour of the incubation period. The purified secretory leader containing fragment was then ligated into the 15 *Bam*HI cleaved pCMVbipep/CI-2A (as described in section A-1) to give rise to pCMVbipepSL/CI-2A. Positive clones were confirmed by DNA sequencing (section A-8) using CTGTATCTGGCGGCTCCGTGG (SEQ ID NO: 16) as primer.

Construction of pCMVbipepER/CI-2A (Fig. 1) was performed by 20 addition of a retention signal to the C-terminus of CI-2A in the context of pCMVbipepSL/CI-2A. The retention signal was added in frame with the CI-2A sequence by PCR using CTAATCTAGACTACAGCTCGTCCTTG TAGTCCTCGAGGCCGACCCTGGGGACCTG (SEQ ID NO: 17) and CGGGATCCATGAAGACAGAGTGGCCAGAG (SEQ ID NO: 18) 25 and pCMVbipep/CI-2A as template. The 237 base pair fragment was digested with *Xba*I instead of *Xho*I and ligated into a *Bam*HI/*Xba*I digested pCMVbipepSL/CI-2A prepared as *Bam*HI/*Xho*I digested pCMVbipep. All reaction parameters were as described for construction of pCMVbipepNLS/CI-2A.

30 1-e: Construction of pCMVbipep/muCI-2A

Two silent mutations were introduced into the CI-2A sequence by a 5 step PCR procedure. The first PCR exchanged C¹⁹² → A (cf. The numbering in SEQ ID NO: 1) and the product was after

purification used as reverse primer for amplification of the CI-2A encoding region in pCMVbi pep/CI-2A. This C¹⁹² → A mutated fragment was used as template for introducing the second mutation substitution of T³⁰⁰ → C (cf. The numbering in SEQ ID NO: 1) and thereby leading to a PCR-product including the previously introduced mutation. The double mutated fragment was used as forward primer to amplify the pCMVbi pep/CI-2A defined reading frame. All the PCRs were done in duplicate and in essence performed as described in section A-2 with 25 cycles of 94°C for 30 seconds, 55°C for 30 seconds, and 72°C for 30 seconds. The products were pooled before purification. In the first PCR, 50 ng of pCMVbi pep/CI-2A was used as template with 50 pmol of the following primers CCGGCCTTATTCCAAGCGGC (SEQ ID NO: 19) and CTGCCGGTGGGTACAATTGTGACCATGG (SEQ ID NO: 20). The 248 base pair product was purified using the QIAquick PCR purification kit (see section A-3) with 50 µl as elution volume (PCR-product 1). The second PCR consisted of 12.5 µl PCR-product 1 and 50 pmol CTGTATCTGGCGGCTCCGTGG (SEQ ID NO: 21) as primers with 50 ng pCMVbi pep/CI-2A as template. The complete reaction was loaded on a 2% agarose gel and 448 base pair product was purified as described in section A-6 (PCR-product 2). This product was then used as template in the third PCR that besides the 12.5 µl PCR-product 2 consisted of 50 pmol CTGTATCTGGCGGCTCCGTGG (SEQ ID NO: 22) and CGAGTTTGTGACAAAGAGGCGGACGCGATCGATGCGATATTCC (SEQ ID NO: 23) leading to amplification of a 248 base pair fragment (PCR-product-3). This fragment was purified as PCR-product 2 before using 12.5 µl as forward primer together with 50 pmol of CCGGCCTTATTCCAAGCGGC (SEQ ID NO: 24) and 50 ng pCMVbi pep/CI-2A as template. The double mutated 448 DNA fragment was after gel purification PCR amplified using 50 pmol of CCGGCCTTATTCCAAGCGGC (SEQ ID NO: 25) and CTGTATCTGGCGGCTCCGTGG (SEQ ID NO: 26). The amplified double mutated fragment was

inserted into pCMVbipep described for construction of pCMVbipep/CI-2A.

1-f: Construction of pFab60/CI-2A and pFAB60/muCI-2A

The fragment of the CI-2A cDNA that encodes amino acids 21-83 of the wild type protein was inserted into the phagemid vector pFAB60 (Johansen et al., 1995, Protein Eng. 10, pp 1063-7). The CI-2A cDNA fragment was amplified by PCR using pCMVbipep/CI-2A as template with 10 pmol of the primers ATTTGCTAGCTGCACAACCAGCAATGGCACTGAAGACAGAGTGGCCAGAGTTGG (SEQ ID NO: 27) and ATAAGAATGCGGCCGCGCCGACCCTGGGGACCTGGGC (SEQ ID NO: 28) in 4 reactions performed under conditions similar to those described under construction of pCMVbipep/CI-2A. The purified 237 base pair fragment and 2 µg pFAB60 were digested in parallel using 10 units *NheI* and *NotI* in 50 µl 1 x NEBuffer 4 including 1 µg/ml bovine serum albumin (see sections A-5 and A-6). The digested 225 and 4655 base pair fragments were subsequently purified using 1% agarose gel and ligated to each other (see section A-7) and A-1, respectively. Correct insertion was finally confirmed by DNA sequencing using CACACAGGAACTATGA (SEQ ID NO: 29) as primer (See section A-8). An identical approach was utilized for constructing pFAB60/muCI-2A except that pCMVbipep/muCI-2A was used as CI-2A cDNA source.

1-g: Construction of pFab60/muCI-2A_{rc}

Substitution of amino acid 59 to 62 in the full length CI-2A sequence with a 19-mer randomly composed amino acid sequence was performed in the context of pCMVbipep/muCI-2A and the modified CI-2A was subsequently moved to pFAB60 following the same procedure as for constructing pFAB60/CI-2A. The coding region for the amino acid sequence was obtained from a synthetic oligo that was amplified by PCR. Four parallel reactions were performed using 12.5 pmol of CTGCCGGTGGGTACAATTGTGCTGCGCTACATGGACCGCGCAATAGTGATGAACGTGAACAT

TAGCGCACGCAAACTACGGATTGATCGCGTCCGCCTCTTTGTCGACAACTCG (SEQ ID NO: 30) as template with 50 pmol of the primers CGAGTTTGTGCGACAAAGAGGCGGAC (SEQ ID NO: 31) and TCTGCCGGTGGGTACAATTG (SEQ ID NO: 32). These reactions were applied to 25 cycles of 94°C for 2.5 minutes, 45°C for 2 minutes, and 72°C for 2 minutes with all other conditions as described in section A-2. The product was purified by phenol/CHCl₃ extraction and dissolved in 30 µl sterile H₂O. To facilitate insertion into muCI-2A, 5 µl of the fragment was supplied with 20 units *MunI* (Boehringer Mannheim), 5 µl 10 x SureCut buffer M (Boehringer Mannheim) and sterile H₂O to adjust the volume to 50 µl, and incubated at 37°C for 4 hours. After addition of 6 µl 10 x *SalI* restriction enzyme buffer and 3 µl H₂O together with 20 units of *SalI* the incubation continued for 4 hours. Purification of the 89 base pair fragment was done using a 2.5% low temperature agarose gel (see section A-6). Preparation of the *MunI*/*SalI* digested pCMVbipep/muCI-2A was in principle similar to the procedure described above. Four µg pCMVbipep were digested with 30 units of *MunI* in a 150 µl reaction followed by addition of 30 units *SalI* in 50 µl 4 x *SalI* restriction enzyme buffer and purified using a 1% gel as described in section A-7. The ligation and confirmation procedures were performed as for the construction of pCMVbipep/CI-2A.

25 1-h: Library construction

The degenerated oligo

TCTGCCGGTGGGTAGAAATTCNNNNKNNKNNKNNKNNKNNKNNKNNKNNKCGGATTGATCGCGTCC GCCTCTTTGTCGACAACTCG (SEQ ID NO: 33) was converted into a double stranded form by an extension reaction. The oligo was mixed with a 3-fold excess of CGAGTTTGTGCGACAAAGAGGCGGAC (SEQ ID NO: 34) in 1 x SuperTaq buffer (Enzyme Technologies Ltd.) including 8 units SuperTaq polymerase (Enzyme Technologies Ltd.) and 0.2 mM dNTP. Heating of the mixture to 94°C for 1 minute followed by 45°C for 2 minutes was done to ensure a

sufficient annealing between the oligos before the temperature was changed to 55°C for 45 minutes to increase polymerase activity. After the reaction was completed, the sample was phenol/CHCl₃ extracted before cleavage of 1/3 of the product with 100 units *EcoRI* and *SalI* in 100 µl 1 x *EcoRI* buffer including 1 µg/ml bovine serum albumin (See section A-6). The complete digested 56 base pair DNA fragment was purified on a 2% low temperature agarose gel (see section A-6) and ligated (see section A-1) into the *MunI*/*SalI* cleaved pCMVbipep/muCI-2A described in Example 1-g. Randomly chosen colonies were sequenced as described for construction of pCMVbipep/CI-2A.

1-i: Subtilisin assay

The cell extracts were diluted to the indicated amounts in 10 µl PBS and added to 25 µl 0.1 M Tris/HCl pH 8.6 containing 5 × 10⁻⁸ M Subtilisin Carlsberg (Sigma). After incubation at 25°C for 30 minutes, 25 µl 0.1 M Tris/HCl pH 8.6 containing 5 mM N-succinyl-Ala-Ala-Pro-Phe-p-Nitroanilide (Sigma) was added and the substrate conversion was followed by measuring the absorbency at 405 nm every two minutes until the reaction had reached exhaustion.

1-j: Cell lines and culturing conditions

All the cells were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal calf serum or 10% new born calf serum, 1% L-glutamine, and 50 µg/ml penicillin/streptomycin and incubated under standard cell culture conditions.

The 293mCAT cells and U2OSmCAT cells are derived from 293 (ATCC# CRL-1573) and U2OS (ATCC# HTB-96) by stable transfection with pmCAT/IRES-hyg. The 293 cells were transfected by the Calcium co-precipitation method outlined for transfection of the Bosc packaging cells and the U2OS cells were transduced using the Eugene transfection kit according to the manufacturer's protocol (Boehringer Mannheim). Stable transfectants

were selected by culturing in the presence of 150-200 μ g active hygromycin B/ml (Sigma). After transducing 293mCAT or U2OSmCAT with retroviral vectors the selection was shifted to 0.6 mg/ml or 0.4 mg/ml genitacin (GibcoBRL), respectively.

- 5 The murine NIH-3T3 cell line (ATCC# CRL-165) was upon transduction with the retroviral vectors cultured in the presence of 0.6 mg/ml genitacin.

1-k: Transduction of NIH-3T3, 293mCAT, and U2OSmCAT cells.

- For production of retroviral vector particles, pCMVbipep
10 derived constructs were transfected into the BOSC packaging cell line using a CaPO_4 co-precipitation method. BOSC packaging cells (also known as BOSC23 cells, cf. WO 94/19478) were diluted to 5×10^5 cells/cm² the day before the transfection and washed once in complete DMEM 2 hours before the transfection.
15 tion. The CaPO_4 co-precipitated mixtures were prepared by diluting 10 mg of pCMVbipep or the pCMVbipep derived construct with 10 mg salmon sperm DNA in 450 ml ddH₂O and adding 50 ml 2.5 M CaCl_2 . These solutions were slowly added to 500 ml $2 \times$ HEPES-buffered saline pH 7.05 (280 mM NaCl, 1.5 mM Na_2HPO_4 , 50
20 mM HEPES/NaOH pH 7.05) under gentle shaking followed by two to five minutes of incubation at 25°C before adding the precipitate to the prepared BOSC cells. After 24 hours of incubation, the cells were washed twice in PBS (137 mM NaCl, 2.7 mM KCl, 8.3 mM Na_2HPO_4 , 1.4 mM KH_2PO_4) and further cultivated in 10 ml
25 DMEM including supplements for another 24 hours. The media from the transfected BOSC cells were collected and diluted from 10 to 10⁵-fold in complete DMEM including 6 mg/ml Polybrene (Sigma). The recipient cells, which had been plated at 10⁴ cells/cm² and incubated at standard cell culture conditions for
30 24 hours in complete DMEM, were exposed to virus-containing media for 24 hours at standard conditions. After this incubation period, the transduced cell were washed twice in PBS and incubated in complete DMEM including genitacin.

1-l: Preparation of total cell extracts

The CMVbipep/CI-2A or CMVbipep transduced NIH-3T3 cells were harvested from two confluent T175 cell flasks by incubation with 5 ml 0.5 × Trypsin-EDTA solution (GibcoBRL)/plate. The recovered cells were diluted 1:1 in complete DMEM and subsequently collected by centrifugation, washed twice in 10 ml complete DMEM and twice in 1 ml PBS. Finally, the cells were suspended in 100 µl PBS. The cells were rendered permeable by three cycles of freezing in liquid nitrogen and thawing by incubation at 37°C and subsequently centrifuged at 20000 × g for 15 minutes to remove cell debris. To inactivate endogenous protease activity, the extracts were incubated at 65°C for 15 minutes and re-centrifuged.

1-m: Preparation of nuclear extracts

Two approximately 80% confluent T-175 cell flasks of each cell line were used. The cells were harvested by addition of 3 ml Trypsin/EDTA solution (GibcoBRL) to each flask followed by centrifugation of the 6 ml cell suspensions. All the following reactions were performed at 4°C using chilled solutions. The harvested cells were washed in 10 ml complete DMEM, 10 ml PBS, and 2 times in 1 ml PBS. After the last wash the cells were suspended in 1 ml NP40 lysis buffer (10 mM Tris/HCl pH 7.4, 10 mM NaCl, 3 mM MgCl₂, and 0.5% NP-40), mildly mixed and incubated on ice for 5 minutes. The cells were then collected by centrifugation at 500 × g at 4°C for 5 minutes and suspended in 1 ml NP-40 buffer and the nuclei were immediately harvested by repeating the centrifugation. Proteins were extracted from the nuclei by suspension in 50 µl low salt buffer (20 mM HEPES pH 7.9, 25% glycerol, 0.02 M KCl, 1.5 mM MgCl₂, 0.2 mM EDTA) followed by addition of 50 µl High salt buffer (Low salt buffer supplied with 1 M KCl). After 30 minutes incubation on ice, the nuclear extract was cleared by centrifugation at 20000 × g for 30 minutes. The supernatants were stored at -20°C.

1-n: SDS-PAGE and Western blots

Samples were supplied with ¼ volume of SDS-load buffer (NOVEX) including 1/10 volume 1 M dithiotreitol and heated to 95°C for 2 minutes before loading on a NuPage (NOVEX) 4-12% gradient SDS-gel in 1 x MES buffer (NOVEX) and run at a constant current of 40 mA. The gels were equilibrated in blotting buffer (10mM CHAPS/NaOH pH 11.0, 10% Methanol, 0.5% SDS) for 5 minutes before transfer of the proteins to a 0.2 µm Obititran BA-S 83 membrane (Schleicher & Schoell) by semi dry blotting for 70 minutes. The membrane was allowed to air dry before blocking 1 hour at room temperature in ECL-buffer (50 mM Tris/HCl pH 7.4, 150 mM NaCl, 5 mM EDTA, 0.5% Gelatin, 0.1% NP-40). After blocking, the ECL-buffer was displaced with anti CI-2A rabbit serum diluted 1:1000 in ECL-buffer and the incubation was continued for 1 hour. The membrane was subsequently washed 3 times, each by incubation for 20 minutes in ECL-buffer before adding 1:5000 fold diluted Horse Radish Peroxidase conjugated goat anti rabbit serum (Dako) in ECL-buffer and incubated and washed as described above. The development of the signal was done using an enhanced chemoluminescent kit according to the manufacturer's protocol (Amersham-Pharmacia).

1-o: Production of anti CI-2A polyclonal antibodies, immunoprecipitation.

Rabbits were immunized with 100 µg full length recombinant CI-2A (generous gift from Dr. Ib G. Clausen, Novo Nordic A/S, Denmark) in complete Freund's adjuvant (Sigma) and boosted 4 times with 3 weeks intervals by injecting 50 µg CI-2A formulated in incomplete Freund's adjuvant. The anti CI-2A response was detected by ELISA with recombinant CI-2A immobilized on a MaxiSorb plate (Nunc). Several dilutions of the CI-2A serum were allowed to bind and subsequently detected with a horse radish peroxidase conjugated goat anti rabbit antibody (Dako). All reactions were performed as described in example 1-p.

30 A-1: Ligation and transformation of *Escherichia coli* by electroporation

- 30 ng vector
- 2 µl fragment (containing a fragment concentration resulting in a 10:1 relation between fragment:vector)
- 2 µl 10 x T4 DNA ligase reaction buffer (New England Biolabs)
- 300 units T4 DNA ligase (New England Biolabs)
- Sterile H₂O to adjust the volume to 20 µl
- 198 cycles consisting of 30°C for 30 seconds and 10°C for 30 minutes followed by 16°C over night

10 The ligation products were transformed into *E. Coli* by electroporation:

- 10 µl of the ligation reaction was dialyzed against 2 ml sterile H₂O
- 2 µl of the dialyzed ligation reaction were mixed with 25 µl competent *E. Coli* in a 0.1 cm electroporation cuvette (Bio-Rad) and pulsed with 2 kV
- Addition of 1 ml of SOC-media (20 g Bacto-Tryptone, 5 g Yeast extract, 0.5 g NaCl, 0.19 KCl, dissolved in 950 ml H₂O and adjusted to pH 7.0 using NaOH and supplied with 50 ml 20% glucose and MgCl₂ to a final concentration of 10 mM before use)
- Incubation at 37°C for 0.5-1 hours before streaking 50 µl - 200 µl on LB plates (100 ml LB (10 g Bacto-Tryptone, 5 g Yeast extract, 5 g NaCl, H₂O to 1 l) including 1.5 g agar and 50 mg/ml carbenicillin)

The electroporation competent *E. Coli* cells were prepared as described below:

- An over night culture was used to inoculate 37°C LB to achieve an OD₆₀₀ below 0.020
- The culture was incubated at 37°C until OD₆₀₀ was between 0.8-1.0 and subsequently chilled on ice

- The chilled culture was harvested by centrifugation
- The harvested bacteria were suspended in 300 ml 10% ice cold glycerol solution
- Repetition of the centrifugation
- 5 - The suspension and centrifugation steps were repeated twice
- The bacteria were suspended in 50 ml 10% ice cold glycerol solution and recollected by centrifugation
- The bacteria were suspended in 10% ice cold glycerol
- 10 - buffer to a final density at $6-12 \times 10^{12}$ cells/ml and stored at -80°C in aliquots

A-2: Polymerase chain reactions using TaqGold™

- 100 ng template
- 10 pmol of specified primers, unless otherwise indicated
- 15 - 5 μl 10 x TaqGold™ reaction buffer (Perkin Elmer)
- 3 μl MgCl_2 solution for TaqGold™ (Perkin Elmer)
- 0.4 μl 25 mM dNTP (dGTP, dCTP, dATP, and dTTP)
- 0.4 μl 5 units/ μl TaqGold™ (Perkin Elmer)
- Sterile H_2O to 50 μl
- 20 - All reactions were initiated by 10 minutes at 95°C and after the specified cycles followed by 72°C for 4 minutes.
- For purification of PCR products see section A-3

A-3: PCR using Vent™ DNA polymerase

- 25 - 100 ng template
- 10 pmol of specified primers, unless other is indicated
- 5 μl 10 x Vent™ DNA Polymerase reaction buffer (New England Biolabs)
- 0.4 μl 25 mM dNTP
- 30 - 0.4 μl 5 units/ μl Vent™ DNA Polymerase (New England Biolabs)

- Sterile H₂O to 50 µl
- All reactions were initiated by 1 minute at 94°C and after the specified cycle program followed by 72°C for 4 minutes

5 The amplified DNA fragments were purified by phenol/CHCl₃ extraction followed by ethanol precipitation if the size was less than 100 base pairs. Otherwise, the QIAquick™ PCR-purification kit was used (Qiagen). The PCR-purification kit was used according to the manufacturer's protocol with 50 µl as
10 the elution volume.

A-4: Phenol/CHCl₃ extraction

- The sample volume adjusted to at least 200 µl with sterile H₂O
- Addition of 1 volume Phenol pH 6.7 (supplier)
- 15 - Mixed extensively and centrifuged.
- Addition of 1 volume phenol/CHCl₃ 1:1 solution to the water phase
- Repeat the mix-spin procedure
- Addition of 1 volume CHCl₃ to the water phase
- 20 - Repeat mix-spin procedure
- Water phase supplied with 1/10 volume 3M NaAc pH 6.0 and 2.5 volume -20°C 96% ethanol
- Centrifuged at 20.000 x g for 20 minutes, displacing the supernatant with 70% ethanol and repeated the centrifuga-
25 tion for 2 minutes
- After the DNA was air dried it was dissolved in sterile H₂O

A-5: Vector preparations

The plasmid DNA used for vector preparations was purified by
30 Qiagen maxi prep columns according to the manufacturer's

- Samples were added 1/6 volume DNA load buffer (60% glycerol, 0.025% Bromphenol blue, 0.025% Xylene Cyanol)
- Loaded on an agarose gel in 1 x TBE (89 mM Tris-borate, 25 89 mM Boratic acid, 2 mM EDTA)
- After a satisfactory separation was achieved the DNA was extracted using the Qiagen gel extraction kit according to the manufacturer's protocol with an elution volume of 50 µl unless otherwise indicated

Total cell extracts were prepared from the transduced NIH-3T3, 293mCAT, and U2OSmCAT cells and analysed for the presence of

CI-2A by western blot to obtain a direct proof of the CI-2A expression (Examples 1-1 and 1-n). A rabbit anti CI-2A serum raised against wild type CI-2A recognized a protein with migration properties that corresponded to that expected for
 5 the CI-2A protein expressed from CMVbipep/CI-2A. Even an overexposure of the western blot did not reveal any bands with similar mobility properties in the extracts derived from pCMVbipep transduced cells thereby showing that soluble CI-2A is expressed by CMVbipep/CI-2A and tolerated by the tested
 10 cell lines.

Interestingly, a CMVbipep/CI-2A specific band with a slightly lower mobility was reproducibly detected by western blots. The nature of this band is uncertain at present. The decreased mobility is consistent with a slight secondary modification
 15 such as a phosphorylation, although no experimental proof exists. Other more trivial and less likely explanations could be a non-consensus start codon use or that the CI-2A stop codon is leaky thereby giving rise to an extended CI-2A protein. The inventors are currently in the process of characterizing the expression products more detailed by N-terminal
 20 amino acid sequencing and Mass spectrometry.

A consistent constrained presentation of a peptide library in a scaffold context demands that the structure of the scaffold is stable in the given environment. Since CI-2A is naturally
 25 found in the seeds of barley, the shift to the environment inside mammalian cells could influence the folding kinetics and thereby the stability of CI-2A. The protease inhibitory activity of CI-2A provides a simple method for assaying functionality (Example 1-i), which reflects the amount of native
 30 folded CI-2A. Increasing amounts of the total cell extracts used for the western blots were pre-incubated with subtilisin before measuring the residual protease active by addition of a chromogenic substrate (Fig. 2). The presence of 0.1-2 µl

extract from CMVbipep/CI-2A transduced cells completely blocked subtilisin activity. In contrast, when increasing the amount of the extracts from CMVbipep transduced cells to as much as 10 μ l no effects on the subtilisin activity was observed. This result proves that the decrease in subtilisin activity observed using extracts from CMVbipep/CI-2A transduced cells is due to expression of CI-2A. Furthermore, the observation that CI-2A extracted from mammalian cells is functional suggests a native structure inside the cells, which support that at random peptide library will be presented by CI-2A in a constrained manner. By comparing the amount of CI-2A containing extract required to inhibit subtilisin to a standard curve based on purified CI-2A, a rough estimation of the active CI-2A concentration can be obtained. This subsequently allows a calculation of the cellular concentration. By doing so, we estimated the CI-2A content in the tested cell lines to be in the μ M range.

The combined evidence from the experiments described above suggests that CI-2A is tolerated as an intracellularly located protein in mammalian cells at a sufficient concentration to exert a biological activity. Furthermore, the pronounced CI-2A activity found in cell extracts indicates a native conformation enabling a constrained peptide presentation from the loop region.

EXAMPLE 3

Expression of CI-2A fusion proteins with a defined subcellular localization

A number of biological reactions are restricted to defined cellular compartments. To increase the probability of selecting peptides that interfere with such types of reactions we

fused amino acid sequences to CI-2A that in other contexts have been shown to direct the fusion protein to a defined subcellular localization. Signals mediating localization to either the endoplasmic reticulum or the nucleus were added to
5 test whether or not a restricted localization of CI-2A could be achieved.

The nuclear localization signal from the SV-40 large T-antigen was fused to the N-terminal of CI-2A thereby giving rise to the pCMVbipepNLS/CI-2A construct (Fig. 1 and Example 1-c).
10 NIH-3T3 cells were transduced with CMVbipepNLS/CI-2A, CMVbipep/CI-2A, and CMVbipep derived retroviral particles. Western blotting and the subtilisin activity assay (see example 1-i and 1-n) were subsequently used to analyze the CI-2A content in total extracts and nuclear extracts prepared from
15 all the transduced cell lines. Neither the total extracts nor the nuclear extracts derived from the CMVbipep transduced cells were able to interfere with the protease activity of subtilisin, consistent with the results described in example 2. In contrast, both the nuclear extracts and the total ex-
20 tracts derived from CMVbipepNLS/CI-2A blocked inhibiting the protease activity of subtilisin whereas only the total extract of CMVbipep/CI-2A exerted CI-2A activity (Fig. 3). Western blotting revealed an equal amount of CI-2A in the total ex-
tracts from CMVbipep/CI-2A and CMVbipepNLS/CI-2A transduced
25 cells, thereby indicating a similar expression level. Consistent with the activity test, the amount of CI-2A detected in the nuclear extracts by western blotting was at least 10-fold higher for NLS/CI-2A than for CI-2A. Thus, two independent types of analysis support that the presence of the NLS results
30 in an increased concentration of NLS/CI-2A in the nucleus.

Endoplasmic reticulum localization requires targeting to this compartment and subsequently an ongoing retention. To achieve this, the pCMVbipepER/CI-2A construct contains a secretoric

By defining the subcellular localization of a peptide library, the likelihood of isolating active peptides interfering with reactions known to be restricted to occur at such locations can be significantly increased. In addition to the examples described above, one could also target CI-2A to other locations such as the cell membrane, mitochondria, lysosomes etc.

EXAMPLE 4

Displaying CI-2A on phage particles

The phage display technology has since its discovery been used extensively for screening of peptide libraries. Phage display
5 can be used in combination with CellScreen™ to enrich the peptide library for binders to e.g. crude cell extracts or whole cells and thereby reduce the number of peptides needed to be handled in the biological screening systems. We therefore tested the applicability of displaying CI-2A at the
10 surface of phage particles by insertion of CI-2A into the pFAB60 phagemid (Fig. 4 and Johansen et al. (1995), Protein Eng. 10, pp 1063-1067). The presence of CI-2A on the surface of pFAB60/CI-2A derived phage particles was verified using
15 both an ELISA assay and the subtilisin assay (Example 1-o & 1-i). In the ELISA assay, immobilized rabbit anti CI-2A polyclonal antibodies retained phage particles derived from pFAB60/CI-2A at levels several orders of magnitude higher than CI-2A negative phage particles (Fig. 5). Consistent with this
20 result, subtilisin activity could only be inhibited by the pFAB60/CI-2A derived phage particles. These two experiments clearly demonstrate that CI-2A can be displayed on the phage surface and therefore fulfill the features necessary for a scaffold protein in both the phage display and the CellScreen™ technologies.

25 The loop region of CI-2A will be extensively modified in the situation where a peptide library is presented by CI-2A. To mimic this situation and test whether phage particles presenting such modified CI-2A proteins could be produced we exchanged 4 amino acids situated in the loop region with a 19-
30 mer randomly composed peptide, thereby generating pFAB60/CI-2A_rc (Fig. 4 and Example 1-g). When analyzed by ELISA, a significant signal was obtained although it was slightly

decreased compared to the phage particles carrying the unmodified CI-2A (Fig. 5). This variation could be due the presence of an important antibody recognition site in the loop region. In conclusion, the fact that phage particles displaying the modified CI-2A generated a signal comparable to that obtained for the pFAB60/CI-2A containing phage particles suggests that CI-2A can be displayed independently of the amino acid composition in the loop region.

EXAMPLE 5

10 *Constructions of CI-2A presented peptide libraries*

To facilitate the exchange of amino acids situated in the loop of CI-2A, recognition sites for *MunI* and *SalI* were introduced into the CI-2A cDNA in pCMVbipep/CI-2A by silent mutagenesis to generate pCMVbipep/muCI-2A (Example 1-e). The presence of the cleavage sites enables a non-PCR based library construction procedure. In this procedure, a synthetic oligo that includes the randomized region is converted into a double stranded form before cloning into the *MunI*/*SalI* sites (Fig. 6). The feasibility of producing a peptide library using this procedure was tested by a small scale ligation followed by sequencing of a limited number of randomly chosen clones. Out of 8 sequenced clones, all contained insertion of the random oligo and none of the insertions encoded identical peptides. This suggests that that transfer of diversity from the synthetic oligo into a biologically active form is possible using this strategy.

The use of the *MunI* site to generate peptide libraries limits the portion of the loop region in CI-2A that can become substituted. To utilize the complete loop region for peptide presentation it is contemplated to create a complementary

peptide library by using the more 5'-located *Bam*HI cleavage site situated in pCMVbi pep. In this case, the DNA fragment that contains the randomized region can be generated by either a non-PCR based or a PCR based method as outlined in Fig. 7.

5 This allows the 5'-border of the randomized region to be defined based on theoretical considerations.

The two combined cloning strategies allow construction of CI-2A presented libraries that diverge in the manner whereby the peptides are presented. Such different libraries are likely to
10 complement each other regarding interactions with possible target molecules. Screening different types of libraries will therefore increase the number of possible target molecules identified.

EXAMPLE 6

15 *Discussion of CI-2A as scaffold in the CellScreen™ technology*

As demonstrated in Example 2, CI-2A can be expressed in a functional form in mammalian cells. Establishment of a functional system for displaying randomized peptide sequences using CI-2A as a scaffold is thus relatively uncomplicated to
20 envisage. In order to direct the CI-2A scaffold to different compartments of the cell, retroviral vectors harboring different leader sequences have been constructed. The data presented in Example 3 illustrates that a defined localization for CI-2A can be obtained. Especially the nucleus and the
25 endoplasmic reticulum are compartments where several specific reactions occur, such as transcriptional regulation and receptor folding. Such processes are obvious targets for peptide antagonists. The intracellular tolerance to CI-2A in mammalian cells and the capability of CI-2A to translocate to the nu-
30 cleus and the endoplasmic reticulum makes it reasonable to

assume that CI-2A can be targeted to other compartments and intracellular organelles if desired.

CI-2A is an extremely stable protein that has the advantage of being small, having no disulfide bridges, no glycosylation
 5 sites and a loop of eight amino acids that protrudes from the core structure (Macphalen C.A. et al. (1983) J. Mol. Biol. 168, pp 445-447). It has been shown that insertion of 7, 9, 11 and 13 residues between the Met40 and Glu41 (corresponding to the Met59 and Glu60 in the native molecule) in CI-2A have a
 10 minimal effect on the stability and folding rates of the protein. Moreover, CI-2A has been found to fold through interactions of key residues in the C-terminal domain of the protein, irrespective of the amino acids situated in the loop region (Osmark P. et al. (1993) Biochem. 32, 11007-11014,
 15 Ladurner A.G. and Fersht A.R. (1997) J. Mol. Biol. 273, pp 330-337). The loop therefore seems to be suitable for the insertion of random residues which is the purpose of the present invention. As described in example 4, substitution of 4 amino acids in the loop region with a 19-mer randomly com-
 20 posed peptide did no significantly affect the capability of this modified CI-2A to be displayed on the phage surface. This result correlates with previous data showing that folding of the CI-2A core structure is independent of both the size and amino acid sequence of the loop region.

25 One important feature of the present invention is that the peptides are selected based on a biological activity exerted inside mammalian cells. This implicates that the stability of the applied scaffold must be independent of disulfide bridge formation. Since no disulfide bridges are present in the CI-2A
 30 structure the stability and the folding rate of CI-2A must be independent of the redox potential of the solvent. The extraction of active CI-2A from mammalian cells suggests that CI-2A is capable of adopting a native structure in the intracellular

environment, which is the major demand to a CellScreen™ scaffold.

The N-terminal 19 amino acid residues do not have any known function for the folding of CI-2A (De Prat Gay G. et al.

5 (1994), Proc. Natl. Acad. Sci. 91, pp 10943-10946 and references herein). As they might be able to perform unspecific interactions during screening and target isolation we decided to use the shorter 64 residue version of CI-2A. In addition, the limited size increases the accessibility of the
10 peptide/CI-2A protein to binding pockets which might increase the number of possible targets and thereby the likelihood for isolation of peptide antagonists.

The ability of CI-2A to be exposed at the surface of phage particles was clearly demonstrated by the data presented in
15 Example 4. The phage display technology allows selection of peptides that interacts with any immobilized component(s). This could be crude cell extracts, receptor containing membranes or partly purified material containing the activity against which a peptide antagonist is desired. At present, a
20 higher diversity can be handled by phage display due to the difference in the physical size of a phage particle and a mammalian cell. By reducing the peptide library to a pool which only contains peptides that are capable of interacting with the potential target molecules the actual diversity that
25 needs to be handled inside the cells, can be significantly reduced

To be able to isolate the CI-2A scaffold - and thereby the target molecule to which it binds - from selected cells, a peptide tag will be fused to the N-terminus of the truncated
30 CI-2A. We are currently considering the following tags: His-tag, Strep-tag or FLAG-tag. However, co-immunoprecipitation using an anti CI-2A antibody can also be used. Alternatively

to the biochemical methods, genetic approaches such as yeast or mammalian two- or three-hybrid systems will also be applied to identify the targets that interacts with the selected peptides.

41129 PC 1

14.26.06.00

1

CLAIMS

1. A method for identifying a modulator in the form of a biologically active polypeptide fragment which is capable of detectably modulating, *in vivo*, a phenotypic trait in a cell, the method comprising the steps of

10 (a) preparing a pool of expression vectors, each vector of said pool containing at least one member from a library of randomly modified nucleotide sequences derived from a parent nucleotide sequence encoding a parent peptide which in vivo directly modulates activity of a known protease, wherein the randomly modified nucleotide sequences comprise

15 - an invariable part encoding a scaffold portion
 of the parent peptide, said scaffold portion
 serving to stabilize said polypeptide fragment
 and being stable towards proteolytic attack
 and/or being insensitive to a reducing
20 environment, and
 - random nucleotides,

25 (b) transforming a population of substantially identical cells with said vectors of said pool so as to obtain transformed cells,

(c) culturing said transformed cells under conditions facilitating expression of said randomly modified nucleotide sequences,

30 (d) examining said transformed cells and isolating transformed cell(s) wherein the preselected phenotypic trait is modulated thereby indicating that the expression product of said randomly modified nucleotide sequence is biologically active, and

M 25.05.00

2

(e) identifying the modulator by determining said randomly modified nucleotide sequence of said vector present in cell(s) isolated in step (d) and/or determining the amino acid sequence of the expression product encoded
5 by said randomly modified nucleotide sequence.

2. The method according to claim 1, wherein the substantially identical cells are prokaryotic cells.

10 3. The method according to claim 1, wherein the substantially identical cells are eukaryotic cells.

4. The method according to claim 3, wherein the eukaryotic cells are selected from the group consisting of fungal cells,
15 protozoan cells, animal cells, and plant cells.

5. The method according to claim 4, wherein the animal cells are selected from the group consisting of mammalian cells, arthropod cells such as insect cells, avian cells, and piscine
20 cells.

6. The method according to any of the preceding claims, wherein the transformed cells examined in step (d) predominantly carries one single copy of the vector.

25

7. The method according to claim 6, wherein transformation step (b) is performed under such conditions that the cells transformed are predominantly or at most transformed with one single vector from said pool, or wherein, prior to carrying
30 out step (d), cells being transformed with more than one vector from said pool are substantially excluded from the further steps.

26-06-2000

1129 PC 1

DK 009900408

M 26.06.00

3

8. The method according to any one of the preceding claims,
wherein the random nucleotides are introduced in part(s) of
the parent nucleotide sequence which encode(s) the active
site(s) of the parent peptide, or the part(s) which encode(s)
5 structure(s) interfering with the active site(s).

9. The method according to any one of the preceding claims,
wherein the invariable part of the nucleotide sequence encodes
truncated parts of the scaffold portion of the parent peptide
10 sufficient to maintain stability.

10. The method according to any of the preceding claims,
wherein the invariable part of the parent nucleotide sequence
encodes a peptide which is free from disulfide bridges.
15

11. The method according to any one of claims 1-9, wherein the
invariable part of the parent nucleotide sequence encodes a
peptide having disulfide bridges.

20 12. The method according to any one of the preceding claims,
wherein the random nucleotides are introduced in the form of
an insertion or a substitution into the parent nucleotide
sequence, optionally in combination with deletion(s) in the
parent nucleotide sequence.

25

13. The method according to claim 12, wherein the number of
random nucleotides which are introduced is in the range from 3
to about 100.

30 14. The method according to any one of the preceding claims,
wherein the random nucleotides are nucleotide sequences and/or
are single random nucleotides introduced at specific sites in
the parent nucleotide sequence.

M 26.06.00

4

15. The method according to any one of the preceding claims, wherein the random nucleotides are selected from the group consisting of

5

- synthetic, completely random deoxyribonucleotides;
- synthetic random DNA sequences, wherein limitation on randomization of some nucleotides is introduced so as to limit the number of available sequences and/or to avoid
10 undesired stop codons and/or to facilitate introduction of post-translational modifications of expressed peptide(s);
- synthetic random DNA sequences as in (1) or (2) coupled to a sequence encoding a purification tag; and
15 - CDR encoding nucleotide sequences isolated from a library of immune-competent cells raised against an antigen.

16. The method according to claim 15, wherein the CDR encoding nucleotide sequences encode CDR-3 peptide sequences.

20

17. The method according to any one of claims 14-16, wherein the random nucleotides are prepared by random codon synthesis where defined DNA codons are synthesized in a random order.

25 18. The method according to claim 17, wherein the relative amount of synthesized codons ensure that all encoded amino acids will be present with substantially the same frequency in the total of encoded polypeptide fragments.

30 19. The method according to any one of the preceding claims, wherein the random nucleotides are introduced into the expression vector by the principle of site directed PCR-mediated mutagenesis.

26-06-2000

21129 PC 1

DK 009900408

11 26.06.00

5

20. The method according to any one of the preceding claims, wherein the parent peptide is an inhibitor of activity of the known protease.

5

21. A method according to claim 20, wherein the inhibitor is selected from the group consisting of a BPTI/Kunitz family protease inhibitor, a serpin family protease inhibitor, a Kazal family protease inhibitor, a soybean trypsin inhibitor (Kunitz) family protease inhibitor, a potato inhibitor I family member, a Bowman-Birk family protease inhibitor, a squash inhibitor family member, a wap-type 'Four-disulfide Core' proteinase inhibitor, a hirudin family protease inhibitor, a factor Xa inhibitor, an Ascaris trypsin inhibitor family member, a cystatin family protease inhibitor, a calpain family cysteine protease inhibitor, a tissue inhibitor of metalloproteinases family member, a carboxypeptidase A inhibitor, a metallocarboxypeptidase inhibitor, and an angiotensin-converting enzyme inhibitor.

20

22. The method according to claim 21, wherein the parent peptide is a potato inhibitor family I member.

23. The method according to claim 22, wherein the parent peptide is chymotrypsin inhibitor 2A (CI-2A).

25

24. The method according to any of the preceding claims wherein the substantially identical cells are mammalian cells and the vector is selected from the group consisting of a retroviral vector, a vaccinia virus vector, an adenoviral vector, an adeno associated virus (AAV) vector, a herpes simplex virus (HSV) vector, an alpha virus vector, and a semliki forest virus vector.

30

41129 PC 1

14.25.05.00

6

26. The method according to claim 25, wherein the retroviral vector is derived from retrovirus selected from the group consisting of Avian Leukosis-Sarcoma Virus (ALSV), Mammalian type C, Mammalian type B, and Lentivirus, and optionally modified with heterologous cis-acting elements.

10

28. The method according to claim 27, wherein the non-identical ends contain non-identical promoters.

29. The method according to any one of claims 25-28, wherein the retroviral vector contains a heterologous promoter replacing the viral promoter in the 5'-LTR, such as a CMV promoter, an RSV promoter, an SV-40 promoter, a TK promoter, an MT promoter, or an inducible system such as Tet or Ecdysone.

30. The method according to any one of claims 25-29, wherein step (a) is carried out by

25

- 1) transfecting suitable packaging cells with vectors which comprise the randomly modified nucleotide sequences and which are integratable in virions produced by said packaging cells,
- 2) culturing said transfected packaging cells in a culture medium under conditions which facilitate production by the packaging cells of virions containing the randomly modified nucleotide sequences,

M 25.05.00

7

- 3) recovering and optionally concentrating said virions, and
- 4) transducing said substantially identical cells with the virions.

5 31. The method according to claim 30, wherein the packaging cells are selected from the group consisting of PE501, Bosc23, Ψ2, GP+E86, PhoenixEco, PA317, GP+AM12, DA(ampho), Bing, FLYA13, ProPak, CRIP, ΨAM, Phoenix-Ampho, PG13, H9 (293GPG), and EcoPack.

10

32. The method according to any one of claims 25-31, wherein the virions are pseudotyped retrovirus produced by an ecotropic packaging cell line so as to confer broad tropism to the virions produced thereby, or wherein an ecotropic receptor has
15 been introduced into the substantially identical cells so as to allow transduction with ecotropic virions.

33. The method according to claim 32, wherein the ecotropic receptor has been introduced in the substantially identical
20 cells by means of transduction.

34. The method according to any of the preceding claims wherein the randomly modified nucleotide sequences are coupled to a nucleotide sequence encoding at least one fusion partner.

25

35. The method according to claim 34, wherein the fusion partner serves to facilitate expression and/or purification/isolation and/or further stabilization of the expression product.

30

36. The method according to claim 35, wherein the fusion partner includes a purification tag such as His₆ tag, myc tag,

M 26.06.00

8

BSP biotinylation target sequence, of BirA, flu tag, lacZ, and GST.

37. The method according to claim 34 or 35, wherein the fusion
5 partner is a sorting signal or a targeting sequence.

38. The method according to claim 37, wherein the sorting
signal is a signal patch or a signal peptide.

10 39. The method according to claim 37 or 38, wherein the sor-
ting signal effects export of the expressed peptide out of the
cell or into the cell membrane, or, when the substantially
identical cells are eukaryotic, into endoplasmic reticulum,
into Golgi apparatus, into lysosomes, into secretory vesicles,
15 into mitochondria, into peroxisomes, or into the nucleus.

40. The method according to any one of the preceding claims,
which further comprises the step of resolving the 3-dimen-
sional structure of the identified modulator.

20

41. A method for the preparation of a replicable expression
vector, the method comprising the steps of identifying a
modulator by the method according to any one of the preceding
claims, and subsequently

25

i) isolating or synthesizing a nucleic acid sequence which
encodes the modulator, and

ii) engineering a replicable expression vector comprising
an operon which comprises, in the 5'-3' direction and
in operable linkage, 1) a promoter for driving

30

expression of the nucleic acid sequence, 2) optionally
a nucleotide sequence encoding a leader peptide, 3) the

26-06-2000

21129 PC 1

DK 009900408

11 25.05.00

9

nucleic acid sequence, and 4) optionally a termination signal.

42. A method for the preparation of a transformed cell carrying a nucleic acid sequence encoding a modulator as defined in any one of claims 1-40, the method comprising transforming a suitable host cell with an expression vector prepared according to claim 41.

43. A method for providing a modulator as defined in any one of claims 1-40, the method comprising

- I) growing a transformed cell prepared according to the method of claim 42 in a culture medium under conditions which facilitates expression by the cell of the randomly modified nucleotide sequence, and
- II) subsequently harvesting the expression product from the cell and/or the culture medium, or
- Ia) identifying the modulator according to the method of any one of claims 1-40, and
- Ib) subsequently synthesizing the modulator by means of chemical synthesis on the basis of the sequence determined in step (e).

44. A method for isolating and/or identifying a target biomolecule, the method comprising providing a modulator according to the method of claim 43 and subsequently using the modulator as an affinity ligand in an affinity purification step so as to isolate the target biomolecule from a suitable sample.

45. The method according to claim 44, wherein the affinity purification step is an affinity chromatographic step, an

26-06-2000

21129 PC 1

DK 009900408

M 26.06.00

10

affinity mass spectrometry step, or a co-immunoprecipitation step.

46. A method for isolating and/or identifying a target biomolecule, the method comprising providing a peptide modulator according to the method of claim 42 and subsequently using the modulator as a probe against a cDNA library derived from the substantially identical cells or using the modulator as bait in a two- or three-hybrid system.

10

47. The method according to any of claims 44-46, wherein the target biomolecule is a peptide or a nucleic acid.

48. The method according to claim 47 further comprising the step of determining the amino acid sequence of the peptide or determining the nucleotide sequence of the nucleic acid.

49. The method according to any of claims 44-48, further comprising the step of resolving the 3-dimensional structure of the target biomolecule.

25

50. A method for selecting a chemical compound as a putative drug candidate in drug development, the method comprising the steps of

- assaying a library of chemical compounds for interaction with a target biomolecule which has been de novo isolated according to the method of any one of claims 44-49, and
- selecting compounds which interact significantly with the target biomolecule.

30

51. The method according to claim 50, wherein the library of chemical compounds has been provided by chemical synthesis

125.06.00

11

upon initial identification of the members of the library by structure-based or non-structure based computer drug-modeling.

5 52. A method for the preparation of a medicinal product, the
method comprising the steps of

A) selecting a chemical compound by the method according to claim 50 or 51,

10 B) performing pre-clinical tests with the chemical compound
in order to assess the suitability thereof as a medicinal
product,

15 C) entering, if the chemical compound is deemed suitable in step (B), clinical trials using the chemical compound in order to obtain market authorization for a medicinal product including the lead compound as a pharmaceutically active substance, and

20 D) upon grant of a market authorization, admixing the chemical compound with a pharmaceutically acceptable carrier, excipient or diluent and marketing the thus obtained medicinal product.

53. A method for developing a medicinal product, the method comprising that a modulator identified according to the method of any one of claims 1-40 serves as a lead compound in the drug development phase or wherein a target biomolecule isolated/identified according to any one of claims 44-49 serves as an interaction probe for the identification of putative drug candidates in the drug discovery phase.


PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12Q 1/68, C12N 15/10		A1	(11) International Publication Number: WO 00/05406
			(43) International Publication Date: 3 February 2000 (03.02.00)
(21) International Application Number: PCT/DK99/00408 (22) International Filing Date: 16 July 1999 (16.07.99) (30) Priority Data: PA 1998 00956 20 July 1998 (20.07.98) DK 60/094,868 29 July 1998 (29.07.98) US (71) Applicant (for all designated States except US): M & E BIOTECH A/S [DK/DK]; Kogle Allé 6, DK-2970 Hørsholm (DK). (72) Inventors; and (75) Inventors/Applicants (for US only): HALKIER, Torben [DK/DK]; Hestkøvej 11 E, DK-3460 Birkerød (DK). JESPERSEN, Lene [DK/DK]; Sørupvej 48, DK-3480 Fredensborg (DK). JENSEN, Allan [DK/DK]; Helsingørsvvej 62, DK-3480 Fredensborg (DK). (74) Agent: KOEFOED, Peter; M & E Biotech A/S, Kogle Allé 6, DK-2970 Hørsholm (DK).		(81) Designated States: AE, AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), EE, EE (Utility model), ES, FI, FI (Utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
(54) Title: NOVEL METHODS FOR THE IDENTIFICATION OF LIGAND AND TARGET BIOMOLECULES			
(57) Abstract			
<p>The invention provides for methods for identification of biologically active biomolecules. In one aspect, a biologically active biomolecule such as RNA or a peptide is identified by incorporating random nucleotide sequences in a scaffold constituted by an enzyme activity modulator, transforming substantially identical host cells with the construct obtained thereby and screening the transformed cells to identify those where a preselected phenotypic trait has been altered. The randomized DNA is subsequently isolated from the phenotypically altered cells and the peptide and/or RNA encoded by the random sequence is determined. In turn, interaction partners which are putative drug targets are identified and isolated by use of the peptide and/or RNA as part of affinity reagents. A preferred scaffold is derived from the potato inhibitor I family of protease inhibitors and exemplified is the barley chymotrypsin inhibitor 2A (CI-2A). Another aspect relates to the identification of novel enzyme inhibitors by using substantially the same approach, but screening specifically for changes in target enzyme activity. Also disclosed are methods of producing the relevant transformation and expression vectors as well as methods for identifying lead compounds and drug targets for use in drug development. Finally, the invention also includes within its scope a method for the preparation of a medicinal product.</p>			
Localization			
Undefined	<p>pCMVbipep/CI-2A</p>		
Nucleus	<p>pCMVbipepNLS/CI-2A</p>		
Secreted	<p>pCMVbipepSL/CI-2A</p>		
Endoplasmic Reticulum	<p>pCMVbipepER/CI-2A</p>		

1/7

**Fig. 1**

2/7







Fig. 2

3/7

**Fig. 3A****Fig. 3B**

4/7

**Fig. 4**

5/7




Fig. 5

6/7




Fig. 6A




Fig. 6B






Fig. 6C

7/7

**Fig. 7A****Fig. 7B**

BIRCH, STEWART, KOLASCH & BIRCH, LLPP.O. Box 747 • Falls Church, Virginia 22040-0747
Telephone: (703) 205-8000 • Facsimile: (703) 205-8050PLEASE NOTE:
YOU MUST
COMPLETE THE
FOLLOWING**COMBINED DECLARATION AND POWER OF ATTORNEY
FOR PATENT AND DESIGN APPLICATIONS**

As a below named inventor, I hereby declare that, my residence, post office address and citizenship are as stated next to my name; that I verily believe that I am the original, first and sole inventor (if only one inventor is named below) or an original, first and joint inventor (if plural inventors are named below) of the subject matter which is claimed and for which a patent is sought on the invention entitled.

Insert Title: NOVEL METHODS FOR THE IDENTIFICATION OF LIGAND AND TARGET BIOMOLECULES

Fill in Appropriate Information -
For Use Without
Specification
Attached: the specification of which is attached hereto. If not attached hereto,
the specification was filed on _____ as
United States Application Number _____;
and amended on _____ (if applicable) and/or
the specification was filed on July 16, 1999 as PCT
International Application Number PCT/DK99/00408; and was
amended under PCT Article 19 on _____ (if applicable)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I do not know and do not believe the same was ever known or used in the United States of America before my or our invention thereof, or patented or described in any printed publication in any country before my or our invention thereof or more than one year prior to this application, that the same was not in public use or on sale in the United States of America more than one year prior to this application, that the invention has not been patented or made the subject of an inventor's certificate issued before the date of this application in any country foreign to the United States of America on an application filed by me or my legal representative or assigns more than twelve months (six months for designs) prior to this application, and that no application for patent or inventor's certificate on this invention has been filed in any country foreign to the United States of America prior to this application by me or my legal representatives or assigns, except as follows

I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)	Priority Claimed
Insert Priority Information: (if appropriate)	
<u>PA 1998 00956</u> (Number)	<u>Denmark</u> (Country)
<u>July 20, 1998</u> (Month/Day/Year Filed)	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<u> </u> (Number)	<u> </u> (Country)
<u> </u> (Month/Day/Year Filed)	<input type="checkbox"/> Yes <input type="checkbox"/> No
<u> </u> (Number)	<u> </u> (Country)
<u> </u> (Month/Day/Year Filed)	<input type="checkbox"/> Yes <input type="checkbox"/> No
<u> </u> (Number)	<u> </u> (Country)
<u> </u> (Month/Day/Year Filed)	<input type="checkbox"/> Yes <input type="checkbox"/> No

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional applications(s) listed below.

Insert Provisional Application(s): (if any)	<u>60/094,868</u> (Application Number)	<u>July 29, 1998</u> (Filing Date)
	<u> </u> (Application Number)	<u> </u> (Filing Date)

All Foreign Applications, if any, for any Patent or Inventor's Certificate Filed More than 12 Months (6 Months for Designs) Prior to the Filing Date of This Application

Country	Application Number	Date of Filing (Month/Day/Year)
Insert Requested Information: (if appropriate)		
<u> </u>	<u> </u>	<u> </u>
<u> </u>	<u> </u>	<u> </u>

I hereby claim the benefit under Title 35, United States Code, §120 of any United States and/or PCT application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States and/or PCT application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose information which is material to the patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

Insert Prior U.S. Application(s): (if any)	<u> </u> (Application Number)	<u> </u> (Filing Date)	<u> </u> (Status - patented, pending, abandoned)
	<u> </u> (Application Number)	<u> </u> (Filing Date)	<u> </u> (Status - patented, pending, abandoned)

Attorney Docket No. 3631-0104P

I hereby appoint the following attorneys to prosecute this application and/or an international application based on this application and to transact all business in the Patent and Trademark Office connected therewith and in connection with the resulting patent based on instructions received from the entity who first sent the application papers to the attorneys identified below, unless the inventor(s) or assignee provides said attorneys with a written notice to the contrary:

Raymond C. Stewart	(Reg. No. 21,066)	Terrell C. Birch	(Reg. No. 19,382)
Joseph A. Kolasch	(Reg. No. 22,463)	James M. Slattery	(Reg. No. 28,380)
Bernard L. Sweeney	(Reg. No. 24,448)	Michael K. Mutter	(Reg. No. 29,680)
Charles Gorenstein	(Reg. No. 29,271)	Gerald M. Murphy, Jr	(Reg. No. 28,977)
Leonard R. Svensson	(Reg. No. 30,330)	Terry L. Clark	(Reg. No. 32,644)
Andrew D. Meikle	(Reg. No. 32,868)	Marc S. Weiner	(Reg. No. 32,181)
Joe McKinney Muncy	(Reg. No. 32,334)	Donald J. Daley	(Reg. No. 34,313)
John W. Bailey	(Reg. No. 32,881)	John A. Castellano	(Reg. No. 35,094)
Gary D. Yacura	(Reg. No. 35,416)		

Send Correspondence to:

BIRCH, STEWART, KOLASCH & BIRCH, LLPor **Customer No. 2292**

P.O. Box 747 • Falls Church, Virginia 22040-0747

Telephone: (703) 205-8000 • Facsimile: (703) 205-8050

**PLEASE NOTE:
YOU MUST
COMPLETE
THE
FOLLOWING:**

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon

Full Name of First
or Sole Inventor:
Insert Name of
Inventor
Insert Date This
Document is Signed

Insert Residence
Insert Citizenship

Insert Post Office
Address

Full Name of Second
Inventor, if any:
see above

Full Name of Third
Inventor, if any:
see above

Full Name of Fourth
Inventor, if any:
see above

GIVEN NAME/FAMILY NAME <u>Torben HALKIER</u>		INVENTOR'S SIGNATURE <i>Tor Halkier</i>	DATE* <u>04. JAN. 2001</u>
Residence (City, State & Country) <u>Solrød Strand DENMARK</u> <i>DKX</i>		CITIZENSHIP Danish	
MAILING ADDRESS (Complete Street Address including City, State & Country) <u>Lyngvej 5, DK-2680 Solrød Strand DENMARK</u>			
GIVEN NAME/FAMILY NAME <u>Lene JESPERSEN</u>		INVENTOR'S SIGNATURE <i>Lene Jespersen</i>	DATE* <u>05.01 2001</u>
Residence (City, State & Country) <u>Fredensborg DENMARK</u> <i>DKX</i>		CITIZENSHIP Danish	
MAILING ADDRESS (Complete Street Address including City, State & Country) <u>Sørupvej 48, DK-3480 Fredensborg DENMARK</u>			
GIVEN NAME/FAMILY NAME <u>Allan JENSEN</u>		INVENTOR'S SIGNATURE <i>Allan Jensen</i>	DATE* <u>09 01 2001</u>
Residence (City, State & Country) <u>Fredensborg Denmark</u> <i>DKX</i>		CITIZENSHIP Danish	
MAILING ADDRESS (Complete Street Address including City, State & Country) <u>Præstemoesvej 1, DK-3480 Fredensborg</u>			
GIVEN NAME/FAMILY NAME		INVENTOR'S SIGNATURE	DATE*
Residence (City, State & Country)		CITIZENSHIP	
MAILING ADDRESS (Complete Street Address including City, State & Country)			

WO 00/05406

PCT/DK99/00408

1

SEQUENCE LISTING

<110> M&E Biotech A/S
Halkier, Torben
Jespersen, Lene
Jensen, Allan

<120> Novel Methods for the Identification of Ligand and
Target Biomolecules

<130> 21129 PC 1

<140>

<141>

<160> 43

<170> PatentIn Ver. 2.1

<210> 1

<211> 451

<212> DNA

<213> Hordeum vulgare

<220>

<221> CDS

<222> (85)..(339)

<220>

<221> mat_peptide

<222> (88)..(336)

<220>

<221> misc_feature

<222> (249)

<223> G is G or T

<220>

<221> misc_feature

<222> (252)

<223> A is A or C

<220>

<221> misc_feature

<222> (279)

<223> C is C or T

<400> 1

cattaaactg atgacatgac agttcaagat ctcacagtca catcggcgat ctaatcagtc 60

WO 00/05406

PCT/DK99/00408

2

```

tcacaggaag cgagcgtaac aagg atg agt tca gtg gag aag aag ccg gag    111
                        Met Ser Ser Val Glu Lys Lys Pro Glu
                          -1  1                      5

gga gtg aac acc ggt gct ggt gac cgt cac aac ctg aag aca gag tgg    159
Gly Val Asn Thr Gly Ala Gly Asp Arg His Asn Leu Lys Thr Glu Trp
      10                      15                      20

cca gag ttg gtg ggg aaa tcg gtg gag gag gcc aag aag gtg att ctg    207
Pro Glu Leu Val Gly Lys Ser Val Glu Glu Ala Lys Lys Val Ile Leu
      25                      30                      35                      40

cag gac aag cca gag gcg caa atc ata gtt ctg ccg gtg ggg aca att    255
Gln Asp Lys Pro Glu Ala Gln Ile Ile Val Leu Pro Val Gly Thr Ile
                        45                      50                      55

gtg acc atg gaa tat cgg atc gac cgc gtc cgc ctc ttt gtc gat aaa    303
Val Thr Met Glu Tyr Arg Ile Asp Arg Val Arg Leu Phe Val Asp Lys
                        60                      65                      70

ctc gac aac att gcc cag gtc ccc agg gtc ggc tag caagcttgag        349
Leu Asp Asn Ile Ala Gln Val Pro Arg Val Gly
                        75                      80

agctagcctg ctgctggcgt gtatgtattg cagcttcacc atctcttctt ggctatagca 409

agattgagat ttataaatca tataacaataa gagttgctgc gg                    451

```

<210> 2
 <211> 84
 <212> PRT
 <213> Hordeum vulgare

```

<400> 2
Met Ser Ser Val Glu Lys Lys Pro Glu Gly Val Asn Thr Gly Ala Gly
  1                      5                      10                      15

Asp Arg His Asn Leu Lys Thr Glu Trp Pro Glu Leu Val Gly Lys Ser
      20                      25                      30

Val Glu Glu Ala Lys Lys Val Ile Leu Gln Asp Lys Pro Glu Ala Gln
      35                      40                      45

Ile Ile Val Leu Pro Val Gly Thr Ile Val Thr Met Glu Tyr Arg Ile
      50                      55                      60

Asp Arg Val Arg Leu Phe Val Asp Lys Leu Asp Asn Ile Ala Gln Val
      65                      70                      75                      80

Pro Arg Val Gly

```

WO 00/05406

PCT/DK99/00408

3

<210> 3
 <211> 27
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic DNA
 primer

 <400> 3
 cgggatccat gaagacagtg gccagag 27

<210> 4
 <211> 28
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic DNA
 primer

 <400> 4
 cgctcgagtc agccgaccct ggggacct 28

<210> 5
 <211> 21
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic DNA
 primer

 <400> 5
 ctgtatctgg cggctccgtg g 21

<210> 6
 <211> 19
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic DNA
 primer

 <400> 6
 acagctggcc ctcgcagac 19

<210> 7

WO 00/05406

PCT/DK99/00408

4

<211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic DNA
 primer

<400> 7
 cccactgctt actggcttat 20

<210> 8
 <211> 19
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic DNA
 primer

<400> 8
 tggggctgca cgtcatttg 19

<210> 9
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic DNA
 primer

<400> 9
 tgtgctacgg cgagtttggt 20

<210> 10
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic DNA
 primer

<400> 10
 ggttcgtgaa aggctccatt 20

<210> 11
 <211> 22

<212> DNA

WO 00/05406

PCT/DK99/00408

6

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic DNA
primer

<400> 15

gaggatccag aatgagcgcc ggtagcag

28

<210> 16

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic DNA
primer

<400> 16

ctgtatcttg cggctccgtg g

21

<210> 17

<211> 55

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic DNA
primer

<400> 17

ctaattctaga ctacagctcg tctttgtagt cctcgaggcc gaccctgggg acctg

55

<210> 18

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic DNA
primer

<400> 18

cgggatccat gaagacagag tggccagag

29

<210> 19

<211> 20

<212> DNA

<213> Artificial Sequence

WO 00/05406

PCT/DK99/00408

7

<220>

<223> Description of Artificial Sequence: Synthetic DNA primer

<400> 19

ccggccttat tccaagcggc

20

<210> 20

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic DNA primer

<400> 20

ctgccggtgg gtacaattgt gaccatgg

28

<210> 21

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic DNA primer

<400> 21

ctgtatctgg cggtccgtg g

21

<210> 22

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic DNA primer

<400> 22

ctgtatctgg cggtccgtg g

21

<210> 23

<211> 44

<212> DNA

<213> Artificial Sequence

<220>

<220>
<223> Description of Artificial Sequence: Synthetic DNA

WO 00/05406

PCT/DK99/00408

9

primer

<400> 27
atttgctagc tgcacaacca gcaatggcac tgaagacaga gtggccagag ttgg 54

<210> 28
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic DNA
primer

<400> 28
ataagaatgc ggccgcgccg accctgggga cctgggc 37

<210> 29
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic DNA
primer

<400> 29
cacacaggaa actatga 17

<210> 30
<211> 115
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic DNA
primer

<400> 30
ctgccggtgg gtacaattgt gctgcgctac atggaccgcg caatagtgat gaacgtgaac 60
attagcgcac gcaaactacg gattgatcgc gtccgcctct ttgtcgacaa actcg 115

<210> 31
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic DNA

WO 00/05406

PCT/DK99/00408

10

primer

<400> 31
cgagtttgtc gacaaagagg cggac 25

<210> 32
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic DNA
primer

<400> 32
tctgccggtg ggtacaattg 20

<210> 33
<211> 83
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
degenerate oligonucleotide

<400> 33
tctgccggtg ggtagaattc nnnknknkn knknknknkn nnknknkcga ttgatcgcg 60
ccgcctcttt gtcgacaaac tcg 83

<210> 34
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic DNA
primer

<400> 34
cgagtttgtc gacaaagagg cggac 25

<210> 35
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Fragment

WO 00/05406

PCT/DK99/00408

11

constituting nuclear localization signal

<400> 35

Met Ala Ala Pro Lys Lys Lys Arg Lys Val Gly Ser
1 5 10

<210> 36

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Fragment
constituting secretion signal

<400> 36

Met Asp Trp Ile Trp Arg Ile Leu Phe Leu Val Gly Ala Ala Thr Gly
1 5 10 15

Ala His Ser Gly Ser
20

<210> 37

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Fragment
constituting retention sequence

<400> 37

Leu Glu Asp Tyr Lys Asp Glu Leu
1 5

<210> 38

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Fragment
constituting random insert

<400> 38

Val Leu Arg Tyr Met Asp Arg Ala Ile Val Met Asn Val Asn Ile Ser
1 5 10 15

WO 00/05406

PCT/DK99/00408

12

Ala Arg Lys Leu Arg Ile Asp
20

<210> 39

<211> 5788

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Hybrid
circular plasmid

<400> 39

```
tgcgcgcgttt cggatgatgac ggtgaaaacc tctgacacat gcagctcccc gagacgggtca 60
cagcttgtct gtaagcggat gccgggagca gacaagcccg tcaggcgcg tcagcgggtg 120
ttggcgggtg tcggggctgg cttaactatg cggcatcaga gcagattgta ctgagagtgc 180
accatatgcg gtgtgaaata ccgcacagat gcgtaaggag aaaataccgc atcaggcgcc 240
attcgccatt caggctgcgc aactgttggg aaggcgatc ggtgcgggcc tcttcgctat 300
tacgccagct ggcgaaaggg ggatgtgctg caaggcgatt aagttgggta acgccagggt 360
tttcccagtc acgacgttgt aaaacgacgg ccagtgaatt ctccggaatt ggctagccta 420
gagtcgcgta cataacttac ggtaaatggc ccgcctggct gaccgcccaa cgacccccgc 480
ccattgacgt caataatgac gtatgttccc atagtaacgc caataggggac tttccattga 540
cgtcaatggg tggagtattt acggtaaaact gccacttgg cagtacatca agtgtatcat 600
atgccaaagta cgcacctat tgacgtcaat gacggtaaat ggcccgcctg gcattatgcc 660
cagtacatga ccttatggga ctttcctact tggcagtaca tctacgtatt agtcatcgct 720
attaccatgg tgatgcgggt ttggcagtac atcaatgggc gtggatagcg gtttgactca 780
cggggatttc caagtctcca cccattgac gtcaatggga gtttgttttg gcacccaaat 840
caacgggact ttccaaaatg tcgtaacaac tccgccccat tgacgcaaat gggcggtagg 900
cgtgtacggt gggagggtcta taaaaagggt aagaacccca cactcggcgc gccagtcctc 960
cgatagactg agtcgccccg gtaccctgtt atccaataaa gccttttgct gttgcatccg 1020
aatcgtgggt tcgctgatcc ttgggagggc ctctcagag tgattgactg cccagcctgg 1080
gggtctttca tttgggggct cgtccgggat ttggagaccc ccgcccaggg accaccgacc 1140
caccgtcggt aggtaaagct gccagcgatc gttttgtctc cgtctctgtc tttgtgcgtg 1200
tgtgtgtgtg tgccgcgcat tactttttgc gctgcgtct gattctgtac tagttagcta 1260
actagatctg tatctggcgg ctccgtggaa gaactgacga gttcgtattc ccgaccgcag 1320
ccctgggaga cgtctcagag gcacgcgggg ggggatccag agctcgagct ttgaaaaaca 1380
cgcgcccgcc atgtagtcta gaacgcgttg atcagttaac gaattcgaag ggtcccaggc 1440
ctcggagatc tgggccccat cggccgcccc ctaacgttac tggccgaagc cgcttggaaat 1500
aaggccgggt tgcgtttgtc tatatgttat tttccaccat attgocgtct tttggcaatg 1560
tgaggggccc gaaacctggc cctgtcttct tgacgagcat tcctaggggt ctttcccctc 1620
tcgcccgaag aatgcaaggc ctgttgaatg tcgtgaagga agcagttcct ctggaagctt 1680
cttgaagaca aacaacgtct gtagcgaccc tttgcaggca gcggaacccc ccacctggcg 1740
acagggtgct ctgcggccaa aagccacgtg tataagatac acctgcaaag gcggcacaac 1800
cccagtgcc cgttgtgagt tggatagttg tggaaagagt caaatggctc tcctcaagcg 1860
tattcaacaa ggggctgaag gatgccaga aggtacccca ttgtatggga tctgatctgg 1920
ggcctcggtg cacatgcttt acatgtgttt agtcgaggtt aaaaaacgtc taggcccccc 1980
gaaccacggg gacgtggttt tcctttgaaa aacacgattg ccgcgtgtgg cctcgaacac 2040
cgagcgaccc tgcagccaat atgggatcgg ccattgaaca agatggattg cacgcagggt 2100
ctccggccgc ttgggtggag aggtatttcg gctatgactg ggcaacaacg acaatcggtc 2160
gctctgatgc cgcgtgttc cggctgtcag cgcagggcg cccggttctt tttgtcaaga 2220
ccgacctgtc cgggtgccctg aatgaactgc aggacgaggc agcgcggtta tcgtggctgg 2280
```

WO 00/05406

PCT/DK99/00408

13

ccacgacggg	cgttccttgc	gcagctgtgc	tcgacgttgt	cactgaagcg	ggaagggact	2340
ggctgctatt	ggcggaagt	ccggggcagg	atctcctgtc	atctcacctt	gctcctgccg	2400
agaaagtatc	catcatggct	gatgcaatgc	ggcggttgca	tacgcttgat	ccggctacct	2460
gcccattcga	ccaccaagcg	aaacatcgca	tcgagcgagc	acgtactcgg	atggaagccg	2520
gtcttgtcga	tcaggatgat	ctggacgaag	agcatcaggg	gctcgcgcc	gccgaactgt	2580
tcgccaggct	caaggcgcg	atgcccagcg	gcgaggatct	cgctcgtgacc	catggcgatg	2640
cctgcttgcc	gaatatcatg	gtggaaaatg	gccgcttttc	tggattcatc	gactgtggcc	2700
ggctgggtgt	ggcggaccgc	tatcaggaca	tagcgttggc	taccctgat	attgctgaag	2760
agcttggcgg	cgaatgggct	gaccgcttcc	tcgtgcttta	cggtatcgcc	gctcccgatt	2820
cgcagcgcat	cgccttctat	cgccttcttg	acgagttctt	ctgacttaag	acaatagaag	2880
attgtaaatc	acgtgaataa	aagattttat	tcagtttaca	gaaagagggg	ggaatgaaag	2940
accccttcat	aaggcttagc	cagctaactg	cagtaacgcc	atthtgcaag	gcatgggaaa	3000
ataccagagc	tgatgttctc	agaaaaacaa	gaacaagcaa	gtacagagag	gctggaaagt	3060
accgggacta	gggccaacaa	ggatatctgt	ggtaacgac	tagggccccg	gcccgaggcc	3120
aagaacagat	ggtccccaga	aacagagagg	ctggaaaagta	ccgggactag	ggccaaacag	3180
gatatctgtg	gtcaagcact	agggccccgg	cccagggcc	agaacagatg	gtccccagaa	3240
atagctaaaa	caacaacagt	ttcaagagac	ccagaaactg	tctcaagggt	ccccagatga	3300
ccggggatca	accccaagcc	tcattttaaac	taaccaatca	gctcgttctt	cgttctgtga	3360
cccgcgctta	ttgctgcccc	gctctataaa	aagggttaaga	acccacact	cggcgcgcc	3420
gtctccgat	agactgagtc	gcccgggtac	ccgtgtatcc	aataaagcct	tttgcgttg	3480
catccgaatc	gtggtctcgc	tgatccttgg	gagggtctcc	tcctctgtcg	ctcgacctgc	3540
aggcatgcaa	gcttggcgta	atcatggtca	tagctgtttc	ctgtgtgaaa	ttgttatccg	3600
ctcacaattc	cacacaacat	acgagccgga	agcataaagt	gtaaagcctg	gggtgcctaa	3660
tgagtgaact	aactcacatt	aattgcgttg	cgctcactgc	ccgctttcca	gtcgggaaac	3720
ctgtcgtgcc	agctgcatta	atgaatcgcc	caacgcgcgg	ggagaggcgg	tttgcgtatt	3780
ggcgctctct	ccgcttcttc	gctcactgac	tcgctgcgct	cggctcgttc	gctgcggcga	3840
gcggtatcag	ctcactcaaa	ggcggttaata	cggttatcca	cagaatcagg	ggataacgca	3900
ggaaagaaca	tgtgagcaaa	aggccagcaa	aaggccagga	accgtaaaaa	ggcgcggttg	3960
ctggcgtttt	tccataggct	ccgccccctt	gacgagcatc	acaaaaatcg	acgctcaagt	4020
cagaggtggc	gaaacccgac	aggactataa	agataccagg	cgtttccccc	tggaagctcc	4080
ctcgtgcgct	ctcctgttcc	gacctgccc	cttaccggat	acctgtccgc	ctttctccct	4140
tcgggaagcg	tggcgctttc	tcaatgctca	cgctgtaggt	atctcagttc	ggtgtaggtc	4200
gttcgctcca	agctgggctg	tgtgcacgaa	cccccgcttc	agcccgaccg	ctgcgcctta	4260
tcgggtaact	atcgtcttga	gtccaacccg	gtaagacacg	acttatcgcc	actggcagca	4320
gccactggta	acaggattag	cagagcgagg	tatgtaggcg	gtgctacaga	gttcttgaag	4380
tggtggccta	actacggcta	cactagaagg	acagtatttg	gtatctgcgc	tctgctgaag	4440
ccagttacct	tcggaaaaag	agttggtagc	tcttgatccg	gcaaaacaa	caccgctggt	4500
agcgggtggt	tttttgtttg	caagcagcag	attacgcgca	gaaaaaaagg	atctcaagaa	4560
gaccccttga	tcttttctac	ggggtctgac	gctcagtgga	acgaaaactc	acgttaaggg	4620
atthtgggtc	tgagattatc	aaaaaggatc	ttcacctaga	tctttttaa	ttaaaaatga	4680
agtttttaaa	caatctaaag	tatatatgag	taaaactggg	ctgacagtta	ccaatgctta	4740
atcagtgaag	cacctatctc	agcgatctgt	ctatttcggt	catccatagt	tgcttgactc	4800
cccgctggtg	agataactac	gatacgggag	ggcttaccat	ctggccccag	tgctgcaatg	4860
ataccgcgag	acccacgctc	accggctcca	gatttatcag	caataaacca	gccagccgga	4920
agggccgagc	gcagaagtgg	tcctgcaact	ttatccgctt	ccatccagtc	tattaattgt	4980
tgccgggaag	ctagagtaag	tagttcgcca	gttaatatgt	tgcgcaacgt	tggtgccatt	5040
gctacaggca	tcgtgggtgc	acgctcgtcg	tttgggtatg	cttcattcag	ctccggttcc	5100
caacgatcaa	ggcgagttac	atgatcccc	atgttgtgca	aaaaagcggt	tagctccttc	5160
ggctctccga	tcgttgtcag	aagtaagttg	gcgcagtggt	tatcactcat	ggttatggca	5220
gcactgcata	attctcttac	tgtcatgcca	tcgtaagat	gcttttctgt	gactgggtgag	5280
tactcaacca	agtcattctg	agaatagtgt	atgcggcgac	cgagttgctc	ttgcccgcg	5340
tcaatacggg	ataataccgc	gccacatagc	agaactttaa	aagtgtcat	cattggaaaa	5400
cgttcttcgg	ggcgaaaact	ctcaaggatc	ttaccgctgt	tgagatccag	ttcgatgtaa	5460

WO 00/05406

PCT/DK99/00408

14

cccactcgtg caccctaactg atcttcagca tcttttactt tcaccagcgt ttctgggtga 5520
gcaaaaacag gaaggcaaaa tgccgcaaaa aagggaataa gggcgacacg gaaatgttga 5580
atactcatac tcttcctttt tcaatattat tgaagcattt atcagggtta ttgtctcatg 5640
agcggataca tatttgaatg tatttagaaa aataaacaaa taggggttcc gcgcacattt 5700
ccccgaaaag tgccacctga cgtctaagaa accattatta tcatgacatt aacctataaa 5760
aataggcgta tcacgaggcc ctttcgtc 5788

<210> 40

<211> 48

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic DNA
primer

<400> 40

ggtcaggaat tctccggaat tggctagcct agagtcggtt acataact 48

<210> 41

<211> 63

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic DNA
primer

<400> 41

gaggactggc ggcgcgagtg tggggttctt acccttttta tagacctccc accgtacacg 60
cct 63

<210> 42

<211> 76

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic DNA
primer

<400> 42

agatctccga ggctgggac ccttcgaatt cgtttaactga tcaacgcgtt ctagactaca 60
tggcggccgc gtgttt 76

<210> 43

<211> 44

<212> DNA

<213> Artificial Sequence

WO 00/05406

PCT/DK99/00408

15

<220>

<223> Description of Artificial Sequence: Synthetic DNA
primer

<400> 43

gggggatcca gagctcgagc ttgaaaaac acgcggccgc catg

44